BioMedLib Search Engine [ goto HOMEPAGE ]

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Quorum-sensing regulation of the biofilm matrix genes (pel) of Pseudomonas aeruginosa.

Although QS regulation of swarming and DNA release has been shown to play important roles in biofilm development, regulation of genes directly involved in biosynthesis of biofilm matrix has not been described.

Here, transcription of the pel operon, essential for the production of a glucose-rich matrix exopolysaccharide, is shown to be greatly reduced in lasI and rhlI mutants.

Chemical complementation of the lasI mutant with 3-oxo-dodecanoyl homoserine lactone restores pel transcription to the wild-type level and biofilm formation ability.

These findings thus connect QS signaling and transcription of genes responsible for biofilm matrix biosynthesis.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Biotechniques. 2000 Nov;29(5):948-50, 952 [11084852.001]

[Cites] Mol Microbiol. 2006 Dec;62(5):1264-77 [17059568.001]

[Cites] J Bacteriol. 2001 Nov;183(22):6676-83 [11673439.001]

[Cites] Mol Microbiol. 2004 Feb;51(3):675-90 [14731271.001]

[Cites] J Bacteriol. 2004 May;186(10):2936-45 [15126453.001]

[Cites] Annu Rev Microbiol. 1987;41:435-64 [3318676.001]

[Cites] Science. 1998 Apr 10;280(5361):295-8 [9535661.001]

[Cites] Mol Microbiol. 1998 Sep;29(6):1321-30 [9781871.001]

[Cites] Dev Cell. 2004 Nov;7(5):745-54 [15525535.001]

[Cites] Proc Natl Acad Sci U S A. 2004 Nov 9;101(45):15833-9 [15505212.001]

[Cites] Trends Microbiol. 2005 Jan;13(1):20-6 [15639628.001]

[Cites] Trends Microbiol. 2005 Jan;13(1):27-33 [15639629.001]

[Cites] Microbiology. 2005 Mar;151(Pt 3):985-97 [15758243.001]

[Cites] Environ Microbiol. 2005 Apr;7(4):459-71 [15816912.001]

[Cites] RNA. 2005 Oct;11(10):1579-87 [16131593.001]

[Cites] Mol Microbiol. 2006 Feb;59(4):1114-28 [16430688.001]

[Cites] FEMS Microbiol Rev. 2006 Mar;30(2):274-91 [16472307.001]

[Cites] Int J Med Microbiol. 2006 Apr;296(2-3):73-81 [16476569.001]

[Cites] Cell Microbiol. 2006 Dec;8(12):1841-9 [17026480.001]

[Cites] J Bacteriol. 2001 Oct;183(19):5529-34 [11544214.001]

(PMID = 17496081.001).

[ISSN] 0021-9193

[Journal-full-title] Journal of bacteriology

[ISO-abbreviation] J. Bacteriol.

[Language] ENG

[Grant] United States / NIGMS NIH HHS / GM / R01 GM058213; United States / NIGMS NIH HHS / GM / GM58213

[Publication-type] Journal Article; Research Support, N.I.H., Extramural

[Publication-country] United States

[Chemical-registry-number] 0 / Bacterial Proteins

[Other-IDs] NLM/ PMC1951888

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Professor Pel and 'glandular fever'].

[Transliterated title] Professor Pel en 'klierkoorts'.

Pieter Klaesz Pel (1852-1919) was professor of internal medicine at the University of Amsterdam, for more than 35 years.

It is contested whether the patients in question had Hodgkin's disease.

[MeSH-major] Hodgkin Disease / history

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20051175.001).

[ISSN] 1876-8784

[Journal-full-title] Nederlands tijdschrift voor geneeskunde

[ISO-abbreviation] Ned Tijdschr Geneeskd

[Language] dut

[Publication-type] Biography; English Abstract; Historical Article; Journal Article; Portraits

[Publication-country] Netherlands

[Personal-name-as-subject] Pel PK

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Membrane glycoprotein M6A promotes mu-opioid receptor endocytosis and facilitates receptor sorting into the recycling pathway.

The interaction of mu-opioid receptor (MOPr) with the neuronal membrane glycoprotein M6a is known to facilitate MOPr endocytosis in human embryonic kidney 293 (HEK293) cells.

To further study the role of M6a in the post-endocytotic sorting of MOPr, we investigated the agonist-induced co-internalization of MOPr and M6a and protein targeting after internalization in HEK293 cells that co-expressed HA-tagged MOPr and Myc-tagged M6a.

We found that M6a, MOPr, and Rab 11, a marker for recycling endosomes, co-localized in endocytotic vesicles, indicating that MOPr and M6a are primarily targeted to recycling endosomes after endocytosis.

Furthermore, co-expression of M6a augmented the post-endocytotic sorting of delta-opioid receptors into the recycling pathway, indicating that M6a might have a more general role in opioid receptor post-endocytotic sorting.

The enhanced post-endocytotic sorting of MOPr into the recycling pathway was accompanied by a decrease in agonist-induced receptor down-regulation of M6a in co-expressing cells.

We tested the physiological relevance of these findings in primary cultures of cortical neurons and found that co-expression of M6a markedly increased the translocation of MOPrs from the plasma membrane to intracellular vesicles at steady state and significantly enhanced both constitutive and agonist-induced receptor endocytosis.

In conclusion, our results strongly indicate that M6a modulates MOPr endocytosis and post-endocytotic sorting and has an important role in receptor regulation.

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18574501.001).

[ISSN] 1748-7838

[Journal-full-title] Cell research

[ISO-abbreviation] Cell Res.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] China

[Chemical-registry-number] 0 / Membrane Glycoproteins; 0 / OPRM1 protein, human; 0 / Receptors, Opioid, mu; EC 2.1.1.- / Methyltransferases; EC 2.1.1.62 / METTL3 protein, human; EC 3.6.1.- / rab GTP-Binding Proteins; EC 3.6.1.- / rab11 protein

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] First case of bacteremia due to chromosome-encoded CfxA3-beta-lactamase-producing Capnocytophaga sputigena in a pediatric patient with acute erythroblastic leukemia.

Bacteremia due to Capnocytophaga sputigena occurred in a 4-year and 9-month-old Japanese girl patient with acute erythroblastic leukemia in Shinshu University Hospital, Japan.

The causative Capnocytophaga sputigena isolate was found to be a beta-lactamase-producer demonstrating to possess cfxA3 gene.

The gene responsible for the production of CfxA3-beta-lactamase was proved to be chromosome-encoded, by means of southern hybridization analysis.

[MeSH-major] Bacteremia / microbiology. Capnocytophaga / isolation & purification. Chromosomes, Bacterial. Leukemia, Erythroblastic, Acute / complications. beta-Lactamases / biosynthesis

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18499560.001).

[ISSN] 0949-2321

[Journal-full-title] European journal of medical research

[ISO-abbreviation] Eur. J. Med. Res.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Germany

[Chemical-registry-number] 0 / Anti-Bacterial Agents; EC 3.5.2.6 / beta-Lactamases

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Clinicopathological characteristics of erythroblast-rich RAEB and AML M6a in children.

The distinction between RAEB, RAEB-T and AML M6a is difficult when erythroblasts in the bone marrow (BM) exceed 50%.

We analyzed 19 children (2 RAEB, 13 RAEB-T and 4 AML M6a) enrolled in a prospective pathological central review in Japan and divided them into two groups according to the myeloblasts percentage among non-erythroid cells in BM: group A (n = 8), 5-19% myeloblasts; group B (n = 11), 20% or more myeloblasts.

Six with group A and seven with group B treated with AML type chemotherapy achieved complete remission.

Five with group A and seven with group B undergoing SCT are alive at a median of 3 years after diagnosis.

Erythroblast-rich RAEB and AML M6a in children have similar characteristics and may belong to a single disease entity.

[MeSH-major] Anemia, Refractory, with Excess of Blasts / pathology. Erythroblasts / pathology. Granulocyte Precursor Cells / pathology. Leukemia, Myeloid, Acute / pathology

[MeSH-minor] Adolescent. Child. Child, Preschool. Female. Humans. Infant. Japan. Leukocyte Count. Male. Prospective Studies. Remission Induction. Stem Cell Transplantation. Time Factors. Transplantation, Homologous

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Pediatr Int. 2005 Oct;47(5):572-4 [16190967.001]

[Cites] Blood. 2006 Jul 15;108(2):419-25 [16609072.001]

[Cites] Leukemia. 2001 Nov;15(11):1713-20 [11681412.001]

[Cites] Br J Haematol. 2003 Jun;121(5):758-67 [12780790.001]

[Cites] Blood. 2001 Sep 15;98(6):1714-20 [11535502.001]

[Cites] Pediatr Blood Cancer. 2007 Jul;49(1):17-22 [16856158.001]

[Cites] Ann Oncol. 1999 Dec;10(12):1419-32 [10643532.001]

[Cites] Br J Haematol. 2002 Apr;117(1):33-9 [11918530.001]

[Cites] Leukemia. 2003 Feb;17(2):277-82 [12592323.001]

[Cites] Leuk Res. 2003 May;27(5):397-404 [12620291.001]

[Cites] Semin Hematol. 1996 Apr;33(2):111-26 [8722682.001]

[Cites] Br J Haematol. 1982 Jun;51(2):189-99 [6952920.001]

[Cites] Am J Clin Pathol. 2005 Aug;124(2):191-8 [16040288.001]

[Cites] Leuk Res. 2002 May;26(5):423-9 [11916513.001]

[Cites] Leukemia. 2002 Aug;16(8):1399-401 [12145675.001]

(PMID = 18951200.001).

[ISSN] 1865-3774

[Journal-full-title] International journal of hematology

[ISO-abbreviation] Int. J. Hematol.

[Language] eng

[Publication-type] Journal Article; Multicenter Study

[Publication-country] Japan

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Glycoprotein M6a is present in glutamatergic axons in adult rat forebrain and cerebellum.

Glycoprotein M6a is a neuronally expressed member of the proteolipid protein (PLP) family of tetraspans.

In vitro studies suggested a potential role in neurite outgrowth and spine formation and previous investigations have identified M6a as a stress-regulated gene.

To investigate whether the distribution of M6a correlates with neuronal structures susceptible to alterations in response to stress, we localized M6a expression in neurons of hippocampal formation, prefrontal cortex and cerebellum using in situ hybridization and confocal immunofluorescence microscopy.

In situ hybridization confirmed that M6a is expressed in dentate gyrus and cerebellar granule neurons and in hippocampal and cortical pyramidal neurons.

Confocal microscopy localized M6a immunoreactivity to distinct sites within axonal membranes, but not in dendrites or neuronal somata.

Moreover, M6a colocalized with synaptic markers of glutamatergic, but not GABAergic nerve terminals.

M6a expression in the adult brain is particularly strong in unmyelinated axonal fibers, i.e. cerebellar parallel and hippocampal mossy fibers.

In contrast, myelinated axons exhibit only minimal M6a immunoreactivity localized exclusively to terminal regions.

The present neuroanatomical data demonstrate that M6a is an axonal component of glutamatergic neurons and that it is localized to distinct sites of the axonal plasma membrane of pyramidal and granule cells.

[MeSH-minor] Animals. Fluorescent Antibody Technique. Gene Expression. Glutamine. In Situ Hybridization. Male. Microscopy, Confocal. RNA, Messenger / analysis. Rats. Rats, Sprague-Dawley. Vesicular Glutamate Transport Proteins / metabolism

Hazardous Substances Data Bank. Glutamine .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18241840.001).

[ISSN] 0006-8993

[Journal-full-title] Brain research

[ISO-abbreviation] Brain Res.

[Language] eng

[Publication-type] Journal Article

[Publication-country] Netherlands

[Chemical-registry-number] 0 / Membrane Glycoproteins; 0 / Nerve Tissue Proteins; 0 / RNA, Messenger; 0 / Vesicular Glutamate Transport Proteins; 0RH81L854J / Glutamine

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Filopodial protrusions induced by glycoprotein M6a exhibit high motility and aids synapse formation.

M6a is a neuronal membrane glycoprotein whose expression diminishes during chronic stress.

M6a overexpression in rat primary hippocampal neurons induces the formation of filopodial protrusions that could be spine precursors.

As the filopodium and spine motility has been associated with synaptogenesis, we analysed the motility of M6a-induced protrusions by time-lapse imaging.

Our data demonstrate that the motile protrusions formed by the neurons overexpressing M6a were more abundant and moved faster than those formed in control cells.

When different putative M6a phosphorylation sites were mutated, the neurons transfected with a mutant lacking intracellular phosphorylation sites bore filopodia, but these protrusions did not move as fast as those formed by cells overexpressing wild-type M6a.

This suggests a role for M6a phosphorylation state in filopodium motility.

Furthermore, we show that M6a-induced protrusions could be stabilized upon contact with presynaptic region.

The behavior of filopodia from M6a-overexpressing cells and control cells was alike.

Thus, M6a-induced protrusions may be spine precursors that move to reach presynaptic membrane.

We suggest that M6a is a key molecule for spine formation during development.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20074218.001).

[ISSN] 1460-9568

[Journal-full-title] The European journal of neuroscience

[ISO-abbreviation] Eur. J. Neurosci.

[Language] eng

[Grant] United States / Howard Hughes Medical Institute / /

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] France

[Chemical-registry-number] 0 / Gpm6a protein, rat; 0 / Membrane Glycoproteins; 0 / Nerve Tissue Proteins; 0 / Recombinant Fusion Proteins

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

: e14592 Background: During the process of malignant transformation, the tumor cell adopts a new form of metabolism, characterized by aerobic glycolysis and altered TCA cycle flux, that enable it to meet the energetic and biosynthetic demands of proliferation.

METHODS: We have characterized the proliferative and metabolic effects of phenformin, a member of the biguanide family of compounds used in the treatment of diabetes, on the bcr-abl expressing K562 erythroleukemia cell line, and compared the resulting phenotype to those of imatinib and rapamycin, two targeted agents used in the treatment of malignant disease.

Phenformin treatment eliminated the mitochondrial contribution to anabolic metabolism, through inhibition of Complex I of the Electron Transport Chain, as demonstrated by reduced oxygen consumption and intracellular ATP levels.

CONCLUSIONS: Our results confirm the importance of metabolism to the proliferation of malignant cells, thereby validating anabolic metabolism's potential for therapeutic intervention.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27963742.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

Advertisement

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Characterization of AZD8931, a potent reversible small molecule inhibitor against epidermal growth factor receptor (EGFR), erythroblastic leukemia viral oncogene homolog 2 (HER2) and 3 (HER3) with a unique and balanced pharmacological profile.

Characterization of a novel tyrosine kinase inhibitor with a potent and balanced profile against EGFR, HER2 (erbB2), and HER3 (erbB3) has been carried out.

These assays have provided unique insights into the pharmacology of these drugs that result from the varying levels of HER and their associated ligands.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27963188.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

: Effective gene therapy for β-thalassemia major (β-TM) requires consistent, high expression of human β-globin (hβ-globin) in red blood cells (RBCs).

Several groups have now shown that lentiviral (LV) vectors stably transmit the hβ/hγ-globin genes and large elements of the locus control region, resulting in correction of the murine thalassemia intermedia (TI) phenotype and survival of mice with the TM phenotype.

We observed a consistent twofold-higher hβ expression from insulated vectors in single-copy mouse erythroleukemia cell clones, an increase that resulted from reduced position effect variegation (PEV) and increased probability of expression from individual integrants.

These studies have important implications for vector design for clinical trials for gene therapy for hemoglobinopathies.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] Copyright © 2007 The American Society of Gene Therapy. Published by Elsevier Inc. All rights reserved.

(PMID = 28182916.001).

[ISSN] 1525-0024

[Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy

[ISO-abbreviation] Mol. Ther.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Rapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signaling.

Primary effusion lymphoma (PEL) appears as an AIDS-defining lymphoma and like Kaposi sarcoma has been linked to Kaposi sarcoma-associated herpesvirus (KSHV).

We find that (1) rapamycin is efficacious against PEL in culture and in a murine xenograft model;.

(2) mTOR, its activator Akt, and its target p70S6 kinase are phosphorylated in PEL;.

This validates sirolimus as a new treatment option for PEL.

Genetic Alliance. consumer health - Primary effusion lymphoma.

MedlinePlus Health Information. consumer health - Lymphoma.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. SIROLIMUS .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Am J Surg Pathol. 1999 Nov;23(11):1393-400 [10555008.001]

[Cites] Cancer Res. 2004 Jul 15;64(14):4790-9 [15256448.001]

[Cites] Nature. 1999 Dec 23-30;402(6764):889-94 [10622254.001]

[Cites] J Infect Dis. 2000 Dec;182(6):1809-10 [11069261.001]

[Cites] Proc Natl Acad Sci U S A. 2001 Jan 2;98(1):136-41 [11134523.001]

[Cites] Clin Infect Dis. 2001 May 15;32(10):1502-5 [11317254.001]

[Cites] Clin Cancer Res. 2001 Jun;7(6):1758-64 [11410517.001]

[Cites] Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10320-5 [11504907.001]

[Cites] Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10314-9 [11504908.001]

[Cites] Cancer. 2001 Dec 15;92(12):3076-84 [11753987.001]

[Cites] J Infect. 2001 Oct;43(3):195-9 [11798259.001]

[Cites] J Biol Chem. 2002 Apr 19;277(16):13907-17 [11847216.001]

[Cites] J Virol. 2002 Jun;76(12):6213-23 [12021355.001]

[Cites] Clin Microbiol Rev. 2002 Jul;15(3):439-64 [12097251.001]

[Cites] Science. 2002 Nov 15;298(5597):1432-5 [12434062.001]

[Cites] Cancer Res. 2002 Dec 15;62(24):7291-7 [12499272.001]

[Cites] J Virol. 2003 May;77(10):5759-73 [12719569.001]

[Cites] Nat Med. 2003 May;9(5):554-61 [12692543.001]

[Cites] Cancer Res. 2003 May 1;63(9):2010-5 [12727810.001]

[Cites] Blood. 2003 May 15;101(10):4115-21 [12531789.001]

[Cites] Cancer Res. 2003 Aug 1;63(15):4472-80 [12907620.001]

[Cites] Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10399-404 [12925741.001]

[Cites] Cancer Cell. 2003 Nov;4(5):343-8 [14667501.001]

[Cites] J Virol. 2004 Feb;78(4):1918-27 [14747556.001]

[Cites] Proc Natl Acad Sci U S A. 2004 Apr 6;101(14):4821-6 [15047889.001]

[Cites] Nat Med. 2004 Jun;10(6):594-601 [15156201.001]

[Cites] Nat Rev Microbiol. 2004 Aug;2(8):656-68 [15263900.001]

[Cites] Methods Mol Biol. 2005;292:449-80 [15507725.001]

[Cites] Cancer Res. 1988 Feb 1;48(3):589-601 [3335022.001]

[Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]

[Cites] Blood. 1995 Aug 15;86(4):1276-80 [7632932.001]

[Cites] Lancet. 1995 Sep 23;346(8978):799-802 [7674745.001]

[Cites] Nat Med. 1995 Dec;1(12):1274-8 [7489408.001]

[Cites] J Exp Med. 1996 May 1;183(5):2385-90 [8642350.001]

[Cites] Blood. 1996 Oct 1;88(7):2648-54 [8839859.001]

[Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Nov 1;13(3):215-26 [8898666.001]

[Cites] J Virol. 1997 Jan;71(1):715-9 [8985403.001]

[Cites] Blood. 1998 Apr 1;91(7):2475-81 [9516148.001]

[Cites] J Exp Med. 1998 Jul 20;188(2):405-8 [9670053.001]

[Cites] N Engl J Med. 1998 Aug 13;339(7):444-9 [9700178.001]

[Cites] J Virol. 1998 Oct;72(10):8309-15 [9733875.001]

[Cites] N Engl J Med. 1998 Nov 5;339(19):1358-63 [9801396.001]

[Cites] Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4546-51 [10200299.001]

[Cites] Leukemia. 1999 Apr;13(4):634-40 [10214873.001]

[Cites] Transplantation. 1999 Apr 27;67(8):1200-1 [10232577.001]

[Cites] Transplantation. 1999 May 15;67(9):1236-42 [10342315.001]

[Cites] Blood. 1999 Jun 15;93(12):4034-43 [10361100.001]

[Cites] J Virol. 1999 Jul;73(7):6136-40 [10364372.001]

[Cites] Blood. 1999 Oct 15;94(8):2871-9 [10515891.001]

[Cites] Nat Cell Biol. 2004 Nov;6(11):1122-8 [15467718.001]

[Cites] Trends Biochem Sci. 2005 Jan;30(1):35-42 [15653324.001]

[Cites] Science. 2005 Feb 18;307(5712):1098-101 [15718470.001]

[Cites] N Engl J Med. 2005 Mar 31;352(13):1317-23 [15800227.001]

[Cites] Clin Cancer Res. 2005 Apr 15;11(8):3102-8 [15837766.001]

[Cites] AIDS Rev. 2005 Jan-Mar;7(1):56-61 [15875661.001]

[Cites] Cancer Res. 2005 Sep 1;65(17):7800-8 [16140948.001]

[Cites] Cancer Cell. 2005 Sep;8(3):179-83 [16169463.001]

[Cites] Cancer Res. 2006 Jan 1;66(1):168-74 [16397229.001]

[Cites] Cancer Res. 2006 Apr 1;66(7):3658-66 [16585191.001]

[Cites] Nat Genet. 2004 Jul;36(7):683-5 [15220917.001]

[Cites] Nat Genet. 2004 Jul;36(7):687-93 [15220918.001]

[Cites] Eur Cytokine Netw. 1999 Dec;10(4):501-8 [10586116.001]

(PMID = 17082322.001).

[ISSN] 0006-4971

[Journal-full-title] Blood

[ISO-abbreviation] Blood

[Language] ENG

[Grant] United States / NHLBI NIH HHS / HL / HL083469; United States / NCI NIH HHS / CA / R01 CA109232; United States / NCI NIH HHS / CA / R01 CA163217; United States / NIDCR NIH HHS / DE / R01 DE018304-02; United States / NCI NIH HHS / CA / CA096500; United States / NIDCR NIH HHS / DE / DE018304-01; United States / NIDCR NIH HHS / DE / R01 DE018304; United States / NIAID NIH HHS / AI / AI057157; United States / NIDCR NIH HHS / DE / R01 DE018304-01; United States / NCI NIH HHS / CA / CA098110; United States / NCI NIH HHS / CA / CA109232; United States / NCI NIH HHS / CA / CA112935; United States / NIDCR NIH HHS / DE / R01 DE018304-03; United States / NIDCR NIH HHS / DE / DE018304-02; United States / NCI NIH HHS / CA / R01 CA098110; United States / NHLBI NIH HHS / HL / R01 HL083469; United States / NIDCR NIH HHS / DE / DE018304-03; United States / NIAID NIH HHS / AI / U54 AI057157; United States / NCI NIH HHS / CA / R01 CA096500

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Cytokines; 0 / RNA, Messenger; W36ZG6FT64 / Sirolimus

[Other-IDs] NLM/ PMC1801055

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] The pel genes of the Pseudomonas aeruginosa PAK strain are involved at early and late stages of biofilm formation.

Biofilm-deficient P. aeruginosa PAK strains affected in a seven-gene cluster called pel were characterized.

The pel genes encode proteins with similarity to components involved in polysaccharide biogenesis, of which PelF is a putative glycosyltransferase.

The pel genes were previously identified in the P. aeruginosa PA14 strain as required for the production of a glucose-rich matrix material involved in the formation of a thick pellicle and resistant biofilm.

However, in PA14, the pel mutants have no clear phenotype in the initiation phase of attachment.

It was shown that pel mutations in the PAK strain had little influence on biofilm initiation but, as in PA14, appeared to generate the least robust and mature biofilms.

Strikingly, by constructing pel mutants in a non-piliated P. aeruginosa PAK strain, an unexpected effect of the pel mutation in the early phase of biofilm formation was discovered, since it was observed that these mutants were severely defective in the attachment process on solid surfaces.

The pel gene cluster is conserved in other Gram-negative bacteria, and mutation in a Ralstonia solanacearum pelG homologue, ragG, led to an adherence defect.

[MeSH-minor] Bacterial Adhesion. Culture Media. DNA Transposable Elements. Gene Expression Regulation, Bacterial. Glycosyltransferases / genetics. Glycosyltransferases / metabolism. Hydrophobic and Hydrophilic Interactions. Multigene Family. Mutation. Polysaccharides, Bacterial / genetics. Polysaccharides, Bacterial / metabolism

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15758243.001).

[ISSN] 1350-0872

[Journal-full-title] Microbiology (Reading, England)

[ISO-abbreviation] Microbiology (Reading, Engl.)

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Bacterial Proteins; 0 / Culture Media; 0 / DNA Transposable Elements; 0 / Polysaccharides, Bacterial; EC 2.4.- / Glycosyltransferases

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] A colorimetric sensor array for identification of toxic gases below permissible exposure limits.

A colorimetric sensor array has been developed for the rapid and sensitive detection of 20 toxic industrial chemicals (TICs) at their PELs (permissible exposure limits).

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Nat Mater. 2003 Jan;2(1):19-24 [12652667.001]

[Cites] Nature. 2000 Aug 17;406(6797):710-3 [10963592.001]

[Cites] Anal Chem. 2009 Aug 1;81(15):6526-33 [20337402.001]

[Cites] Anal Chem. 2009 Jul 1;81(13):5281-90 [19563211.001]

[Cites] Org Lett. 2008 Oct 16;10(20):4405-8 [18783231.001]

[Cites] Nat Chem. 2009 Oct;1(7):562-7 [20160982.001]

[Cites] Anal Chem. 2006 Jun 1;78(11):3591-600 [16737212.001]

[Cites] Angew Chem Int Ed Engl. 2005 Jul 18;44(29):4528-32 [16003792.001]

[Cites] MRS Bull. 2004 Oct;29(10):720-5 [15991401.001]

[Cites] Acc Chem Res. 2004 Sep;37(9):663-72 [15379582.001]

[Cites] J Org Chem. 2007 Feb 2;72(3):687-99 [17253783.001]

(PMID = 20221484.001).

[ISSN] 1364-548X

[Journal-full-title] Chemical communications (Cambridge, England)

[ISO-abbreviation] Chem. Commun. (Camb.)

[Language] ENG

[Grant] United States / NIEHS NIH HHS / ES / U01 ES016011; United States / NIEHS NIH HHS / ES / U01 ES016011-04; United States / NIEHS NIH HHS / ES / U01ES016011

[Publication-type] Journal Article; Research Support, N.I.H., Extramural

[Publication-country] England

[Chemical-registry-number] 0 / Gases

[Other-IDs] NLM/ NIHMS229286; NLM/ PMC2976522

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] PEL: an unbiased method for estimating age-dependent genetic disease risk from pedigree data unselected for family history.

Providing valid risk estimates of a genetic disease with variable age of onset is a major challenge for prevention strategies.

This article focuses on ascertainment through at least one affected and presents an estimation method based on maximum likelihood, called the Proband's phenotype exclusion likelihood or PEL for estimating age-dependent penetrance using disease status and genotypic information of family members in pedigrees unselected for family history.

We studied the properties of the PEL and compared with another method, the prospective likelihood, in terms of bias and efficiency in risk estimate.

For that purpose, family samples were simulated under various disease risk models and under various ascertainment patterns.

We showed that, whatever the genetic model and the ascertainment scheme, the PEL provided unbiased estimates, whereas the prospective likelihood exhibited some bias in a number of situations.

As an illustration, we estimated the disease risk for transthyretin amyloid neuropathy from a French sample and a Portuguese sample and for BRCA1/2 associated breast cancer from a sample ascertained on early-onset breast cancer cases.

[MeSH-minor] Age Factors. Amyloid Neuropathies / genetics. Bias (Epidemiology). Breast Neoplasms / genetics. France. Genes, BRCA1. Genes, BRCA2. Humans. Likelihood Functions. Models, Genetic. Models, Statistical. Pedigree. Phenotype. Portugal. Prealbumin / genetics. Risk

MedlinePlus Health Information. consumer health - Genetic Disorders.

HAL archives ouvertes. Full text from .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] 2008 Wiley-Liss, Inc.

[Cites] Genomics. 1999 Dec 15;62(3):369-76 [10644434.001]

[Cites] Eur J Hum Genet. 2007 Aug;15(8):831-6 [17473834.001]

[Cites] J Med Genet. 2001 Jan;38(1):43-7 [11332399.001]

[Cites] J Med Genet. 2002 May;39(5):335-9 [12011152.001]

[Cites] Genet Epidemiol. 2003 Apr;24(3):173-80 [12652521.001]

[Cites] J Med Genet. 2003 Nov;40(11):e120 [14627687.001]

[Cites] Genet Epidemiol. 2004 Sep;27(2):109-17 [15305327.001]

[Cites] Hum Hered. 1971;21(6):523-42 [5149961.001]

[Cites] Clin Genet. 1977 Oct;12(4):208-12 [334399.001]

[Cites] Genet Epidemiol. 1990;7(6):391-407 [2292365.001]

[Cites] Am J Hum Genet. 1995 Jan;56(1):265-71 [7825587.001]

[Cites] Am J Hum Genet. 1995 Jan;56(1):33-43 [7825595.001]

[Cites] Genet Epidemiol. 1995;12(1):13-25 [7713397.001]

[Cites] Hum Mol Genet. 1997 Jan;6(1):105-10 [9002677.001]

[Cites] Am J Hum Genet. 1997 May;60(5):1021-30 [9150149.001]

[Cites] Am J Hum Genet. 1998 Mar;62(3):676-89 [9497246.001]

[Cites] Am J Epidemiol. 1998 Oct 1;148(7):623-30 [9778168.001]

[Cites] Ann Oncol. 1998 Sep;9(9):939-50 [9818066.001]

[Cites] Genet Epidemiol. 1999;16(1):15-39 [9915565.001]

[Cites] Am J Hum Genet. 1959 Mar;11(1):1-16 [13626932.001]

[Cites] Genes Chromosomes Cancer. 2005 Aug;43(4):404-13 [15887246.001]

[Cites] Am J Hum Genet. 2000 Mar;66(3):1119-31 [10712222.001]

(PMID = 19089844.001).

[ISSN] 1098-2272

[Journal-full-title] Genetic epidemiology

[ISO-abbreviation] Genet. Epidemiol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Prealbumin

[Other-IDs] NLM/ HALMS358140; NLM/ PMC3108000

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Connecting quorum sensing, c-di-GMP, pel polysaccharide, and biofilm formation in Pseudomonas aeruginosa through tyrosine phosphatase TpbA (PA3885).

This screen identified the PA3885 mutant, which had 147-fold more biofilm than the wild-type strain.

Whole transcriptome analysis showed that loss of PA3885 activated expression of the pel locus, an operon that encodes for the synthesis of extracellular matrix polysaccharide.

Genetic screening identified that loss of PelABDEG and the PA1120 protein (which contains a GGDEF-motif) suppressed the phenotypes of the PA3885 mutant, suggesting that the function of the PA3885 protein is to regulate 3,5-cyclic diguanylic acid (c-di-GMP) concentrations as a phosphatase since c-di-GMP enhances biofilm formation by activating PelD, and c-di-GMP inhibits swarming.

Loss of PA3885 protein increased cellular c-di-GMP concentrations; hence, PA3885 protein is a negative regulator of c-di-GMP production.

Las-mediated quorum sensing positively regulates expression of the PA3885 gene.

These results show that the PA3885 protein responds to AHL signals and likely dephosphorylates PA1120, which leads to reduced c-di-GMP production.

This inhibits matrix exopolysaccharide formation, which leads to reduced biofilm formation; hence, we provide a mechanism for quorum sensing control of biofilm formation through the pel locus and suggest PA3885 should be named TpbA for tyrosine phosphatase related to biofilm formation and PA1120 should be TpbB.

COS Scholar Universe. author profiles.

Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .

Hazardous Substances Data Bank. L-TYROSINE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Bacteriol. 2007 Nov;189(22):8154-64 [17586642.001]

[Cites] Curr Opin Microbiol. 2007 Dec;10(6):644-8 [17981495.001]

[Cites] J Bacteriol. 2008 Apr;190(8):2671-9 [18245294.001]

[Cites] J Biol Chem. 2008 Apr 11;283(15):9933-44 [18256026.001]

[Cites] Appl Microbiol Biotechnol. 2008 Jul;79(5):843-58 [18481058.001]

[Cites] Proc Natl Acad Sci U S A. 1999 Nov 23;96(24):13904-9 [10570171.001]

[Cites] Nature. 2000 Aug 31;406(6799):959-64 [10984043.001]

[Cites] J Bacteriol. 2000 Nov;182(21):5990-6 [11029417.001]

[Cites] Trends Microbiol. 2000 Nov;8(11):498-504 [11121759.001]

[Cites] Mol Microbiol. 2002 Feb;43(3):809-21 [11929534.001]

[Cites] Clin Microbiol Rev. 2002 Apr;15(2):155-66 [11932228.001]

[Cites] Mol Microbiol. 2002 Oct;46(2):571-86 [12406230.001]

[Cites] J Bacteriol. 2003 Feb;185(3):1027-36 [12533479.001]

[Cites] J Bacteriol. 2003 Apr;185(7):2080-95 [12644477.001]

[Cites] J Biol Chem. 2003 Apr 18;278(16):13627-32 [12556522.001]

[Cites] J Biol Chem. 2003 Apr 18;278(16):14429-41 [12562757.001]

[Cites] Mol Microbiol. 2004 Feb;51(3):675-90 [14731271.001]

[Cites] Arch Microbiol. 2004 Mar;181(3):171-81 [14745484.001]

[Cites] Appl Microbiol Biotechnol. 2004 May;64(4):515-24 [14727089.001]

[Cites] J Bacteriol. 2004 Jul;186(14):4466-75 [15231778.001]

[Cites] Mol Microbiol. 2004 Aug;53(4):1075-87 [15306012.001]

[Cites] Proc Natl Acad Sci U S A. 1979 Apr;76(4):1648-52 [377280.001]

[Cites] Proc Natl Acad Sci U S A. 1980 Dec;77(12):7347-51 [7012838.001]

[Cites] J Bacteriol. 1986 Mar;165(3):1002-10 [3005231.001]

[Cites] J Biol Chem. 1990 Nov 5;265(31):18933-43 [2172238.001]

[Cites] Methods Enzymol. 1991;201:477-82 [1943774.001]

[Cites] Science. 1993 May 21;260(5111):1127-30 [8493556.001]

[Cites] Annu Rev Microbiol. 1993;47:597-626 [8257110.001]

[Cites] J Bacteriol. 1995 Feb;177(3):654-9 [7836299.001]

[Cites] Proc Natl Acad Sci U S A. 1995 Jun 20;92(13):5910-4 [7597052.001]

[Cites] Proc Natl Acad Sci U S A. 1995 Jul 3;92(14):6424-8 [7604006.001]

[Cites] Mol Microbiol. 2008 Jul;69(2):376-89 [18485075.001]

[Cites] Mol Microbiol. 2008 Sep;69(5):1153-64 [18573179.001]

[Cites] J Mol Biol. 2008 Nov 7;383(2):414-23 [18775435.001]

[Cites] Trends Microbiol. 2008 Oct;16(10):496-506 [18775660.001]

[Cites] J Bacteriol. 2009 Jan;191(1):169-77 [18952786.001]

[Cites] Microb Biotechnol. 2009 Jan;2(1):62-74 [21261882.001]

[Cites] Proteins. 1991;11(2):95-110 [1946347.001]

[Cites] Biochem J. 1995 Nov 1;311 ( Pt 3):921-7 [7487952.001]

[Cites] J Biochem. 1996 Dec;120(6):1055-63 [9010748.001]

[Cites] J Bacteriol. 1997 May;179(10):3127-32 [9150205.001]

[Cites] Science. 1998 Apr 10;280(5361):295-8 [9535661.001]

[Cites] Bioinformatics. 1998;14(4):378-9 [9632836.001]

[Cites] Annu Rev Biophys Biomol Struct. 1998;27:133-64 [9646865.001]

[Cites] Mol Microbiol. 1998 Oct;30(2):285-93 [9791174.001]

[Cites] Mol Microbiol. 1998 Oct;30(2):295-304 [9791175.001]

[Cites] J Bacteriol. 1998 Dec;180(23):6384-8 [9829950.001]

[Cites] Biotechnol Bioeng. 2004 Dec 5;88(5):630-42 [15470704.001]

[Cites] Mol Microbiol. 2005 Jan;55(2):368-80 [15659157.001]

[Cites] Infect Immun. 2005 Apr;73(4):1954-63 [15784535.001]

[Cites] Proc Natl Acad Sci U S A. 2005 Oct 4;102(40):14422-7 [16186483.001]

[Cites] J Microbiol. 2005 Oct;43(5):443-50 [16273037.001]

[Cites] J Bacteriol. 2006 Jan;188(1):305-16 [16352847.001]

[Cites] J Mol Microbiol Biotechnol. 2005;9(3-4):125-31 [16415586.001]

[Cites] Int J Med Microbiol. 2006 Apr;296(2-3):83-91 [16483840.001]

[Cites] J Biol Chem. 2006 Mar 24;281(12):8090-9 [16418169.001]

[Cites] Curr Opin Microbiol. 2006 Apr;9(2):218-28 [16530465.001]

[Cites] Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2833-8 [16477005.001]

[Cites] Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2839-44 [16477007.001]

[Cites] Microbiology. 2006 Jun;152(Pt 6):1679-86 [16735731.001]

[Cites] DNA Res. 2005;12(5):291-9 [16769691.001]

[Cites] Appl Environ Microbiol. 2006 Jul;72(7):5027-36 [16820502.001]

[Cites] J Bacteriol. 2007 May;189(9):3603-12 [17337585.001]

[Cites] J Bacteriol. 2007 Jul;189(14):5383-6 [17496081.001]

[Cites] Nat Cell Biol. 2007 Jul;9(7):797-803 [17558395.001]

[Cites] J Bacteriol. 2007 Sep;189(18):6695-703 [17631636.001]

[Cites] Environ Microbiol. 2007 Oct;9(10):2475-85 [17803773.001]

[Cites] Mol Microbiol. 2007 Sep;65(6):1474-84 [17824927.001]

[Cites] J Bacteriol. 2007 Nov;189(22):8165-78 [17586641.001]

(PMID = 19543378.001).

[ISSN] 1553-7374

[Journal-full-title] PLoS pathogens

[ISO-abbreviation] PLoS Pathog.

[Language] ENG

[Grant] United States / NIBIB NIH HHS / EB / R01 EB003872

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Adhesins, Bacterial; 0 / Bacterial Proteins; 0 / Glycolipids; 0 / Polysaccharides, Bacterial; 0 / rhamnolipid; 42HK56048U / Tyrosine; 61093-23-0 / bis(3',5')-cyclic diguanylic acid; EC 3.1.3.48 / Protein Tyrosine Phosphatases; H2D2X058MU / Cyclic GMP

[Other-IDs] NLM/ PMC2691606

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Cloning and preliminary characterization of a GATC-specific beta2-class DNA:m6A methyltransferase encoded by transposon Tn1549 from Enterococcus spp.

A recent study revealed a subfamily of N6-adenine (m6A) methyltransferases that comprises a few functionally studied eukaryotic members acting on mRNA and prokaryotic members acting on DNA as well as numerous uncharacterized open reading frames.

Here, we report cloning and functional characterization of a prokaryotic member of this family encoded by transposon Tn1549 from Enterococcus spp.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16450842.001).

[ISSN] 1733-1331

[Journal-full-title] Polish journal of microbiology

[ISO-abbreviation] Pol. J. Microbiol.

[Language] ENG

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Poland

[Chemical-registry-number] 0 / DNA Transposable Elements; 0 / DNA, Bacterial; EC 2.1.1.72 / Site-Specific DNA-Methyltransferase (Adenine-Specific)

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Leukotriene A4 hydrolase expression in PEL cells is regulated at the transcriptional level and leads to increased leukotriene B4 production.

Primary effusion lymphoma (PEL) is a herpesvirus-8-associated lymphoproliferative disease characterized by migration of tumor cells to serous body cavities.

PEL cells originate from postgerminal center B cells and share a remarkable alteration in B cell transcription factor expression and/or activation with classical Hodgkin's disease cells.

Comparative analysis of gene expression by cDNA microarray of BCBL-1 cells (PEL), L-428 (classical Hodgkin's disease), and BJAB cells revealed a subset of genes that were differentially expressed in BCBL-1 cells.

Among these, four genes involved in cell migration and chemotaxis were strongly up-regulated in PEL cells: leukotriene A4 (LTA4) hydrolase (LTA4H), IL-16, thrombospondin-1 (TSP-1), and selectin-P ligand (PSGL-1).

Up-regulation of LTA4H was investigated at the transcriptional level.

Formation of a specific DNA-protein complex in this region was confirmed by EMSA.

[MeSH-minor] Cell Line, Tumor. Enzyme Activation / genetics. Gene Expression Profiling. Hodgkin Disease / genetics. Humans. Inflammation / genetics. Inflammation / immunology. Interleukin-16 / physiology. Membrane Glycoproteins / biosynthesis. Membrane Glycoproteins / genetics. Membrane Glycoproteins / physiology. Promoter Regions, Genetic. RNA, Messenger / biosynthesis. Thrombospondin 1 / biosynthesis. Thrombospondin 1 / genetics. Thrombospondin 1 / physiology. Transcription, Genetic

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16709867.001).

[ISSN] 0022-1767

[Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)

[ISO-abbreviation] J. Immunol.

[Language] eng

[Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Interleukin-16; 0 / Membrane Glycoproteins; 0 / P-selectin ligand protein; 0 / RNA, Messenger; 0 / Thrombospondin 1; 1HGW4DR56D / Leukotriene B4; EC 3.3.2.- / Epoxide Hydrolases; EC 3.3.2.- / leukotriene A4 hydrolase

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] KSHV-infected PEL cell lines exhibit a distinct gene expression profile.

We analyzed the gene expression profiles of lymphocyte-originated tumor cell lines - primary effusion lymphoma (PEL) cell lines, T-cell leukemia (TCL) cell lines, Burkitt lymphoma (BL) cell lines - and two sets of normal peripheral blood mononuclear cells (PBMCs) - in order to determine characteristic gene expression profiles for each of the former three groups.

And we found that these cell lines showed respective typical gene expression profiles and classified into clear four groups, PEL, TCL, BL, and normal PBMCs.

Two B lymphocyte-originated tumor cell lines, PEL and BL cell lines, clearly exhibited distinct gene expression profiles, respectively.

Even though there was only one line that was co-infected with both Kaposi's sarcoma-associated herpesvirus (KSHV) and Epstein-Barr virus (EBV), KSHV seemed to govern the gene expression profile of the co-infected line.

These data suggested not only that established typical tumor cell lines show a distinct gene expression profile but also that this profile may be governed by certain viruses.

[MeSH-major] Gene Expression Regulation, Neoplastic. Gene Expression Regulation, Viral. Herpesvirus 8, Human. Lymphoma, Primary Effusion / genetics. Lymphoma, Primary Effusion / virology

[MeSH-minor] Angiopoietin-1 / genetics. Cell Line, Tumor. Gene Expression Profiling. Humans

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] Copyright 2010 Elsevier Inc. All rights reserved.

(PMID = 20175997.001).

[ISSN] 1090-2104

[Journal-full-title] Biochemical and biophysical research communications

[ISO-abbreviation] Biochem. Biophys. Res. Commun.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Angiopoietin-1

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Detection and sequence analysis of an altered pectate lyase gene in Pseudomonas syringae pv. glycinea and related bacteria.

Pectate lyase (PL) is a potent cell wall-degrading enzyme known to play a role in the microbial infection of plants.

However, the PL gene (pel) was detected by Southern hybridization in four out of four P. syringae pv. glycinea strains examined.

A P. syringae pv. glycinea pel gene was cloned, sequenced, and predicted to encode a protein sharing 70%-90% identity in amino acid sequence with PLs produced by pectolytic pseudomonads and xanthomonads.

A series of amino acid and nucleotide sequence analyses reveal that (i) the predicted P. syringae pv. glycinea PL contains two regions in the amino acid sequence that may affect the formation of a beta-helix structure important for the enzyme activity, and (ii) the P. syringae pv. glycinea pel gene contains a single-base insertion, a double-base insertion, and an 18-bp deletion, which can lead to the synthesis of an inactive PL protein.

The altered pel sequence was also detected by polymerase chain reaction and nucleotide sequencing in the genomes of other pathovars of P. syringae, including phaseolicola and tagetis.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17215896.001).

[ISSN] 0008-4166

[Journal-full-title] Canadian journal of microbiology

[ISO-abbreviation] Can. J. Microbiol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] Canada

[Chemical-registry-number] EC 4.2.2.- / Polysaccharide-Lyases; EC 4.2.2.2 / pectate lyase

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Integration of two essential virulence modulating signals at the Erwinia chrysanthemi pel gene promoters: a role for Fis in the growth-phase regulation.

Production of the essential virulence factors, called pectate lyases (Pels), in the phytopathogenic bacterium Erwinia chrysanthemi is controlled by a complex regulation system and responds to various stimuli, such as the presence of pectin or plant extracts, growth phase, temperature and iron concentration.

Eight regulators modulating the expression of the pel genes (encoding Pels) have been characterized.

Although many studies have been carried out, the mechanisms of control of Pel production by growth phase have not yet been elucidated.

Here we report that a fis mutant of E. chrysanthemi showed a strong increase in transcription of the pel genes during exponential growth whereas induction of expression in the parental strain occurred at the end of exponential growth.

This reveals that Fis acts to prevent an efficient transcription of pel genes at the beginning of exponential growth and also provides evidence of the involvement of Fis in the growth-phase regulation of the pel genes.

By using in vitro DNA-protein interactions and transcription experiments, we find that Fis directly represses the pel gene expression at the transcription initiation step.

In addition, we show that Fis acts in concert with KdgR, the main repressor responding to the presence of pectin compounds, to shut down the pel gene transcription.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18028312.001).

[ISSN] 0950-382X

[Journal-full-title] Molecular microbiology

[ISO-abbreviation] Mol. Microbiol.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Bacterial Proteins; 0 / KdgR protein, Erwinia chrysanthemi; 0 / Repressor Proteins; 0 / Transcription Factors; 9007-49-2 / DNA; EC 4.2.2.- / PelE protein, Erwinia chrysanthemi; EC 4.2.2.- / Polysaccharide-Lyases; EC 4.2.2.2 / pectate lyase

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Pulmonary evaluation of permissible exposure limit of syntroleum S-8 synthetic jet fuel in mice.

No significant changes in respiratory permeability were exhibited, indicating that there was no loss of epithelial barrier integrity following S-8 exposure.

However, morphological examination and morphometric analysis of distal lung tissue, by using transmission electron microscopy, revealed cellular damage in alveolar type II epithelial cells, with significant increases in volume density of lamellar bodies/vacuoles at 352 and 616 S-8 mg/m(3).

Moreover, terminal bronchiolar Clara injury, as evidenced by apical membrane blebs, was observed at relatively low concentrations, suggesting if this synthetic jet fuel is utilized, the current permissible exposure limit of 350 mg/m(3) for hydrocarbon fuels should cautiously be applied.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Toxicol Pathol. 2000 Sep-Oct;28(5):656-63 [11026600.001]

[Cites] Electrophoresis. 1999 Dec;20(18):3659-69 [10612293.001]

[Cites] Toxicol Ind Health. 2001 Feb;17(1):23-9 [12004922.001]

[Cites] Toxicology. 2002 Jun 14;175(1-3):235-45 [12049851.001]

[Cites] Toxicol Sci. 2003 Dec;76(2):347-56 [14514957.001]

[Cites] Toxicology. 2004 Apr 15;197(2):139-47 [15003324.001]

[Cites] Toxicol Lett. 2004 Apr 1;149(1-3):301-8 [15093277.001]

[Cites] J Toxicol Environ Health A. 2004 Jul 23;67(14):1109-29 [15205027.001]

[Cites] Toxicol Appl Pharmacol. 1984 Aug;75(1):44-51 [6464021.001]

[Cites] Scand J Work Environ Health. 1985 Dec;11(6):433-7 [4095521.001]

[Cites] Am J Pathol. 1986 Jun;123(3):454-64 [3717299.001]

[Cites] Hepatology. 1995 May;21(5):1361-72 [7737643.001]

[Cites] J Appl Toxicol. 1996 May-Jun;16(3):197-200 [8818858.001]

[Cites] Toxicol Ind Health. 1997 Jan-Feb;13(1):43-55 [9098949.001]

[Cites] J Occup Environ Med. 1997 Jul;39(7):623-32 [9253723.001]

[Cites] Am J Physiol. 1999 Feb;276(2 Pt 1):L229-38 [9950884.001]

[Cites] Am J Respir Cell Mol Biol. 1999 Jul;21(1):44-53 [10385592.001]

[Cites] Toxicol Sci. 1999 Sep;51(1):119-25 [10496683.001]

[Cites] J Chromatogr A. 2005 Nov 4;1093(1-2):11-20 [16233866.001]

[Cites] Environ Health Perspect. 2006 Feb;114(2):182-5 [16451852.001]

[Cites] J Toxicol Sci. 2006 Aug;31(3):219-28 [16960432.001]

[Cites] Am J Respir Cell Mol Biol. 2006 Oct;35(4):479-87 [16690985.001]

[Cites] Int J Toxicol. 2007 Jul-Aug;26(4):325-9 [17661223.001]

[Cites] Toxicol Sci. 2007 Dec;100(2):415-22 [17890764.001]

[Cites] J Appl Toxicol. 2008 May;28(4):543-53 [17966119.001]

[Cites] Toxicology. 2008 Dec 5;254(1-2):106-11 [18930109.001]

[Cites] Am J Respir Cell Mol Biol. 1996 Jul;15(1):1-8 [8679213.001]

[Cites] Toxicol Sci. 2000 Dec;58(2):290-8 [11099641.001]

(PMID = 19357071.001).

[ISSN] 1096-0929

[Journal-full-title] Toxicological sciences : an official journal of the Society of Toxicology

[ISO-abbreviation] Toxicol. Sci.

[Language] ENG

[Grant] United States / NIEHS NIH HHS / ES / P30 ES006694; United States / NIEHS NIH HHS / ES / ES06694

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.

[Publication-country] United States

[Chemical-registry-number] 0 / Hydrocarbons; 0 / S-8 fuel

[Other-IDs] NLM/ PMC2683924

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Subtype C1 persistent infection of HHV-8 in a PEL patient.

PEL, a rare type of lymphoma constituting less than 5% of NHLs, has been recently identified as a distinct clinical and pathological entity among the B-cell lymphomas, with characteristic morphologic, immunophenotypic, molecular and viral features.

Using a combination of clinical, morphological, immunohistochemical features and molecular biology techniques in this study we document a PEL case with persistent HHV-8 of genotype C1 infection.

[MeSH-minor] Adult. Amino Acid Sequence. Base Sequence. Follow-Up Studies. Genotype. Greece / ethnology. Hodgkin Disease. Humans. Male. Molecular Sequence Data. Phylogeny. Sequence Alignment. Viral Proteins / chemistry. Viral Proteins / genetics

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16194897.001).

[ISSN] 1042-8194

[Journal-full-title] Leukemia & lymphoma

[ISO-abbreviation] Leuk. Lymphoma

[Language] eng

[Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / K1 protein, Human herpesvirus 8; 0 / Viral Proteins

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Antisense inhibition of a pectate lyase gene supports a role for pectin depolymerization in strawberry fruit softening.

It has been reported previously that inhibiting the expression of pectate lyase genes by antisense technology in strawberry (Fragaria x ananassa Duch.) fruit resulted in prolonged fruit firmness.

In this present study, three independent transgenic lines were identified exhibiting a greater than 90% reduction in pectate lyase transcript abundance.

These results indicate that pectate lyase plays an important degradative role in the primary wall and middle lamella in ripening strawberry fruit, and should be included in synergistic models of cell wall disassembly.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Exp Bot. 2001 Aug;52(361):1635-45 [11479328.001]

[Cites] Plant Mol Biol. 2001 Sep;47(1-2):311-40 [11554479.001]

[Cites] Planta. 2001 Nov;214(1):11-21 [11762160.001]

[Cites] Planta. 2001 Dec;214(2):257-64 [11800390.001]

[Cites] Plant Physiol. 2002 Feb;128(2):751-9 [11842178.001]

[Cites] J Exp Bot. 2002 Oct;53(377):2115-9 [12324535.001]

[Cites] Plant Physiol. 2007 Aug;144(4):1693-6 [17687051.001]

[Cites] Planta. 2003 Oct;217(6):951-61 [12838420.001]

[Cites] Plant Physiol. 1997 Jul;114(3):1071-6 [9232883.001]

[Cites] Plant Mol Biol. 1997 Aug;34(6):867-77 [9290639.001]

[Cites] Anal Biochem. 1998 Mar 15;257(2):107-11 [9514779.001]

[Cites] Plant Physiol Biochem. 2004 Dec;42(10):823-31 [15596102.001]

[Cites] Plant Physiol. 2007 Jun;144(2):1012-28 [17449643.001]

[Cites] J Exp Bot. 2003 Feb;54(383):633-45 [12554706.001]

(PMID = 18522930.001).

[ISSN] 1460-2431

[Journal-full-title] Journal of experimental botany

[ISO-abbreviation] J. Exp. Bot.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Pectins; 0 / Plant Proteins; 9000-69-5 / pectin; EC 4.2.2.- / Polysaccharide-Lyases; EC 4.2.2.2 / pectate lyase

[Other-IDs] NLM/ PMC2486476

[Keywords] NOTNLM ; Cell wall / Fragaria / fruit ripening / pectate lyase / pectinases / strawberry

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Organ-specific, developmental, hormonal and stress regulation of expression of putative pectate lyase genes in Arabidopsis.

Pectate lyases catalyse the eliminative cleavage of de-esterified homogalacturonan in pectin, a major component of the primary cell walls in higher plants.

In the completed genome of Arabidopsis, there are 26 genes (AtPLLs) that encode pectate lyase-like proteins.

Interestingly, all PLL genes are expressed in flowers.

Analysis of expression of all PLL genes in seedlings treated with hormones, abiotic stresses and elicitors of defense responses revealed significant changes in the expression of some PLLs without affecting the other PLLs.

The stability of transcripts of PLLs varied considerably among different genes.

[MeSH-major] Arabidopsis / genetics. Arabidopsis Proteins / genetics. Gene Expression Regulation, Plant. Polysaccharide-Lyases / genetics

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17447910.001).

[ISSN] 0028-646X

[Journal-full-title] The New phytologist

[ISO-abbreviation] New Phytol.

[Language] eng

[Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.

[Publication-country] England

[Chemical-registry-number] 0 / Arabidopsis Proteins; 0 / Deoxyadenosines; 0 / RNA, Messenger; 73-03-0 / cordycepin; EC 4.2.2.- / Polysaccharide-Lyases; EC 4.2.2.2 / pectate lyase

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Development of permissible exposure limits: the California experience.

The California OSHA Airborne Contaminant Advisory Committee reviewed several hundred substances and recommended occupational exposure limits with the intent of worker and employer protection.

[MeSH-major] Advisory Committees / organization & administration. Hazardous Substances / standards. Occupational Exposure / standards. Occupational Health / legislation & jurisprudence

[MeSH-minor] Animals. California. Communication. Humans. Maximum Allowable Concentration. National Institute for Occupational Safety and Health (U.S.) / standards. No-Observed-Adverse-Effect Level. Program Development. United States

MedlinePlus Health Information. consumer health - Occupational Health.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16967831.001).

[ISSN] 1077-3525

[Journal-full-title] International journal of occupational and environmental health

[ISO-abbreviation] Int J Occup Environ Health

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Hazardous Substances

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Sub classification and clinico-hematological correlation of 40 cases of acute erythroleukemia - can proerythroblast/myeloblast and proerythroblast/total erythroid cell ratios help subclassify?

The clinico-hematological profile of 40 cases of acute erythroleukemia (AEL) was evaluated.

These were subclassified into three types, namely AML M6a, M6b and M6c based on the myeloblast and proerythroblast percentages.

As AEL is biologically an "erythroid predominant" disease, two ratios (PE/MB, PE/TEC) with proerythroblasts as numerator have been formulated.

An attempt has been made to assess the difference in these ratios in subclassified AEL.

There were 29 M6a, 2M6b,and 9 M6 c patients, which were subclassified using the criteria proposed by Mazzella et al.

The incidence of AEL in our study was 3.7%, predominantly affecting males with a predilection to younger age in contrast to Western studies.

Both PE/MB and PE/TEC ratios were higher in M6b and M6c in comparison to M6a.

The subclassification of AEL becomes essential especially in the era of lineage-targeted therapies, which can lead to the development and use of erythroid specific treatments in the near future.

[MeSH-major] Leukemia, Erythroblastic, Acute / classification

[MeSH-minor] Adult. Age Factors. Aged. Cell Count. Erythroblasts. Erythroid Cells. Female. Granulocyte Precursor Cells. Humans. Incidence. Male. Middle Aged. Sex Factors

Genetic Alliance. consumer health - Acute Erythroleukemia.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17852448.001).

[ISSN] 1607-8454

[Journal-full-title] Hematology (Amsterdam, Netherlands)

[ISO-abbreviation] Hematology

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Efficient secretory expression of an alkaline pectate lyase gene from Bacillus subtilis in E. coli and the purification and characterization of the protein.

The gene encoding pectate lyase (PL) from Bacillus subtilis WSHB04-02 was amplified by PCR, fused with a periplasmic secretion signal peptide sequence, pelB, from pET22b(+), cloned and expressed in Escherichia coli cells using a temperature control vector, pHsh.

[MeSH-minor] Enzyme Activation. Enzyme Stability. Gene Expression Regulation, Bacterial / physiology. Gene Expression Regulation, Enzymologic / physiology. Genetic Enhancement / methods. Recombinant Proteins / biosynthesis. Recombinant Proteins / chemistry

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17237974.001).

[ISSN] 1573-6776

[Journal-full-title] Biotechnology letters

[ISO-abbreviation] Biotechnol. Lett.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Netherlands

[Chemical-registry-number] 0 / Recombinant Proteins; EC 4.2.2.- / Polysaccharide-Lyases; EC 4.2.2.2 / pectate lyase

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] In vivo comparison of epithelial responses for S-8 versus JP-8 jet fuels below permissible exposure limit.

This study was designed to characterize and compare the pulmonary effects in distal lung from a low-level exposure to jet propellant-8 fuel (JP-8) and a new synthetic-8 fuel (S-8).

A pulmonary function test performed 24h after the final exposure indicated that there was a significant increase in expiratory lung resistance in the S-8 mice, whereas JP-8 mice had significant increases in both inspiratory and expiratory lung resistance compared to control values.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Electrophoresis. 1999 Dec;20(18):3659-69 [10612293.001]

[Cites] Toxicology. 2004 Apr 15;197(2):139-47 [15003324.001]

[Cites] Toxicol Sci. 2000 Dec;58(2):290-8 [11099641.001]

[Cites] Am J Physiol Lung Cell Mol Physiol. 2002 May;282(5):L1075-81 [11943673.001]

[Cites] Toxicol Ind Health. 2001 Feb;17(1):23-9 [12004922.001]

[Cites] Am J Respir Cell Mol Biol. 2002 Aug;27(2):170-8 [12151308.001]

[Cites] Toxicol Sci. 2003 Dec;76(2):347-56 [14514957.001]

[Cites] J Med Dent Sci. 2003 Sep;50(3):195-202 [15074357.001]

[Cites] Toxicol Lett. 2004 Apr 1;149(1-3):301-8 [15093277.001]

[Cites] J Toxicol Environ Health A. 2004 Jul 23;67(14):1109-29 [15205027.001]

[Cites] Acta Psychiatr Scand. 1979 Jul;60(1):39-49 [474176.001]

[Cites] Acta Psychiatr Scand Suppl. 1983;303:55-67 [6575584.001]

[Cites] Toxicol Appl Pharmacol. 1984 Aug;75(1):44-51 [6464021.001]

[Cites] Scand J Work Environ Health. 1985 Dec;11(6):433-7 [4095521.001]

[Cites] Am J Pathol. 1986 Jun;123(3):454-64 [3717299.001]

[Cites] Toxicol Ind Health. 1995 May-Jun;11(3):325-36 [7482572.001]

[Cites] Am J Respir Cell Mol Biol. 1996 Jul;15(1):1-8 [8679213.001]

[Cites] J Appl Toxicol. 1996 May-Jun;16(3):197-200 [8818858.001]

[Cites] Toxicol Ind Health. 1997 Jan-Feb;13(1):43-55 [9098949.001]

[Cites] J Occup Environ Med. 1997 Jul;39(7):623-32 [9253723.001]

[Cites] Am J Physiol. 1999 Feb;276(2 Pt 1):L229-38 [9950884.001]

[Cites] Drug Chem Toxicol. 1999 Feb;22(1):155-64 [10189576.001]

[Cites] Am J Respir Cell Mol Biol. 1999 Jul;21(1):44-53 [10385592.001]

[Cites] Toxicol Sci. 1999 Sep;51(1):119-25 [10496683.001]

[Cites] Phys Med Biol. 2005 Apr 7;50(7):1405-19 [15798332.001]

[Cites] J Chromatogr A. 2005 Nov 4;1093(1-2):11-20 [16233866.001]

[Cites] Environ Health Perspect. 2006 Feb;114(2):182-5 [16451852.001]

[Cites] J Toxicol Sci. 2006 Aug;31(3):219-28 [16960432.001]

[Cites] Am J Respir Cell Mol Biol. 2006 Oct;35(4):479-87 [16690985.001]

[Cites] Int J Toxicol. 2007 Jul-Aug;26(4):325-9 [17661223.001]

[Cites] J Appl Toxicol. 2008 May;28(4):543-53 [17966119.001]

[Cites] Toxicol Pathol. 2000 Sep-Oct;28(5):656-63 [11026600.001]

(PMID = 18930109.001).

[ISSN] 0300-483X

[Journal-full-title] Toxicology

[ISO-abbreviation] Toxicology

[Language] ENG

[Grant] United States / NIEHS NIH HHS / ES / ES006694-14; United States / NIEHS NIH HHS / ES / P30 ES006694; United States / NIEHS NIH HHS / ES / ES06694; United States / NIEHS NIH HHS / ES / P30 ES006694-14

[Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] Ireland

[Chemical-registry-number] 0 / Hydrocarbons; 0 / JP8 aviation fuel; 0 / S-8 fuel

[Other-IDs] NLM/ NIHMS208577; NLM/ PMC2927360

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Pure erythroid leukemia with hemophagocytosis.

Biochemistry showed increased ferritin levels.

Pure erythroid leukemia with hemophagocytic syndrome (HPS) was diagnosed.

Complete remission was attained, and HPS also improved.

However, leukemia relapsed during chemotherapy and the patient died.

This is the first report of pure erythroid leukemia complicated with HPS.

[MeSH-major] Leukemia, Erythroblastic, Acute / complications. Lymphohistiocytosis, Hemophagocytic / etiology

Hazardous Substances Data Bank. CYTARABINE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19755777.001).

[ISSN] 1349-7235

[Journal-full-title] Internal medicine (Tokyo, Japan)

[ISO-abbreviation] Intern. Med.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Japan

[Chemical-registry-number] 0 / Antineoplastic Agents; 04079A1RDZ / Cytarabine; X4W7ZR7023 / Methylprednisolone; ZRP63D75JW / Idarubicin

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Primary effusion lymphoma (PEL) is an aggressive neoplasm caused by human herpes virus-8 infection, and is generally resistant to chemotherapy.

Hybrid liposomes, composed of dimyristoylphosphatidylcholine (DMPC) and polyoxyethylene (21) dodecyl ether (C12(EO)21) (HL-21), were rapidly accumulated in the membrane of PEL cells.

HL-21 also increased membrane fluidity of PEL cells, and induced caspase-3 activation along with cell death.

These results suggest that HL-21 should be an effective and attractive regent for PEL treatment.

Genetic Alliance. consumer health - Primary effusion lymphoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] 2010 Elsevier Inc. All rights reserved.

(PMID = 20138834.001).

[ISSN] 1090-2104

[Journal-full-title] Biochemical and biophysical research communications

[ISO-abbreviation] Biochem. Biophys. Res. Commun.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Liposomes; 0AWH8BFG9A / polidocanol; 30IQX730WE / Polyethylene Glycols; U86ZGC74V5 / Dimyristoylphosphatidylcholine

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Primary effusion lymphoma (PEL) is an incurable, aggressive B-cell malignancy that develops rapid resistance to conventional chemotherapy.

MG-132, a proteasome inhibitor, suppresses cell proliferation and induces apoptosis in several PEL cell lines.

Treatment of PEL cells with MG-132 results in downregulation of S-phase kinase protein 2 (SKP2) and accumulation of p27Kip1.

Furthermore, MG-132 treatment of PEL cells causes Bax conformational changes, leading to loss of mitochondrial membrane potential and release of cytochrome c to the cytosole.

Such cytochrome c release results in sequential activation of caspases and apoptosis, while pretreatment of PEL cells with universal inhibitor of caspases, z-VAD-fmk prevents cell death induced by MG-132.

Finally, our data demonstrated in PEL cells that MG-132 downregulates the expression of inhibitor of apoptosis proteins XIAP, cIAP1 and survivin.

Altogether, these findings suggest that MG-132 is a potent inducer of apoptosis of PEL cells via downregulation of SKP2 leading to accumulation of p27Kip1, resulting in cell cycle arrest and apoptosis and strongly suggest that targeting the proteasomal pathway may provide a novel therapeutic approach for the treatment of PEL.

[MeSH-major] Antineoplastic Agents / pharmacology. Apoptosis. Cyclin-Dependent Kinase Inhibitor p27 / metabolism. Gene Expression Regulation, Neoplastic. Leupeptins / pharmacology. Lymphoma, Primary Effusion / drug therapy. Lymphoma, Primary Effusion / pathology. S-Phase Kinase-Associated Proteins / metabolism

Genetic Alliance. consumer health - Primary effusion lymphoma.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19557642.001).

[ISSN] 1029-2403

[Journal-full-title] Leukemia & lymphoma

[ISO-abbreviation] Leuk. Lymphoma

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

[Chemical-registry-number] 0 / Amino Acid Chloromethyl Ketones; 0 / Antineoplastic Agents; 0 / BIRC5 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Leupeptins; 0 / Microtubule-Associated Proteins; 0 / S-Phase Kinase-Associated Proteins; 0 / X-Linked Inhibitor of Apoptosis Protein; 0 / XIAP protein, human; 0 / benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone; 133407-82-6 / benzyloxycarbonylleucyl-leucyl-leucine aldehyde; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27; 9007-43-6 / Cytochromes c

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Primary effusion lymphoma (PEL) is a rare subtype of non-Hodgkin's lymphoma, which is associated with infection by Kaposi's sarcoma herpesvirus (KSHV)/human herpesvirus-8.

However, no structural abnormalities were found in the c-myc oncogene in PEL.

Given that c-Myc is often involved in lymphomagenesis, we hypothesized that it is deregulated in PEL.

We report that PEL cells have abnormally stable c-Myc protein.

Our data show that the impaired c-Myc degradation in PEL cells is associated with a significant underphosphorylation of c-Myc T58.

Conversely, when LANA is eliminated from PEL cells using RNA interference, GSK-3beta-mediated c-Myc T58 phosphorylation is restored.

The presence of c-Myc and LANA in GSK-3beta-containing complexes in PEL cells further confirms the significance of these interactions in naturally KSHV-infected cells.

[MeSH-minor] B-Lymphocytes / metabolism. B-Lymphocytes / virology. Cell Line. Glycogen Synthase Kinase 3 / metabolism. Humans. RNA Interference. Threonine / metabolism

Genetic Alliance. consumer health - Primary effusion lymphoma.

PhosphoSitePlus. gene/protein/disease-specific - PhosphoSitePlus® - comprehensive post-translational modification resource .

Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

Hazardous Substances Data Bank. L-Threonine .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17310999.001).

[ISSN] 0950-9232

[Journal-full-title] Oncogene

[ISO-abbreviation] Oncogene

[Language] eng

[Grant] United States / NCI NIH HHS / CA / R01 CA068939

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Antigens, Viral; 0 / Nuclear Proteins; 0 / Proto-Oncogene Proteins c-myc; 0 / latency-associated nuclear antigen; 2ZD004190S / Threonine; EC 2.7.11.1 / glycogen synthase kinase 3 beta; EC 2.7.11.26 / Glycogen Synthase Kinase 3

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Recent studies of acute erythroleukemias have reaffirmed DiGuglielmo's syndrome (M6a, myeloblast-predominant) and disease (M6b, pronormoblast-predominant).

A 20-year retrospective study was performed to identify cases demonstrating >or=50% erythrocytic component and <30% calculated blasts (FAB exclusion criteria) without underlying cause (96 cases).

[MeSH-major] Erythroblasts. Leukemia, Erythroblastic, Acute / pathology. Models, Statistical. Myelodysplastic Syndromes / pathology

[MeSH-minor] Age Factors. Disease-Free Survival. Erythrocyte Count. Erythrocytes / pathology. Granulocyte Precursor Cells / pathology. Humans. Male. Middle Aged. Multivariate Analysis. Platelet Count. Predictive Value of Tests. Prognosis. Retrospective Studies

MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16755568.001).

[ISSN] 0361-8609

[Journal-full-title] American journal of hematology

[ISO-abbreviation] Am. J. Hematol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Two common albumin assays, bromcresol green (BCG) and agarose gel protein electrophoresis (PEL), frequently yield discordant results, creating confusion regarding which assay is superior for use in myeloma.

METHODS: We measured albumin by BCG on a Roche Modular system, by PEL with a Helena SPIFE SPE Vis agarose gel, and by immunonephelometry performed on a Dade Behring BNII nephelometer.

BCG and PEL were used to measure albumin in 5777 patient samples, and all 3 methods were used in an additional 252 samples.

RESULTS: For sera with zero/low monoclonal immunoglobulin protein (M)-spike (0 to <15 g/L), results for both BCG and PEL correlated well to nephelometry, although median PEL results were 8 g/L lower than corresponding BCG measurements.

Correlation between PEL and nephelometry or BCG diminished with increasing M-spike, with PEL eventually overestimating albumin compared with both other assays.

For 35% of myeloma patients, discrepancy between BCG and PEL had a potentially clinically significant effect on staging, but no difference in group survival was found.

CONCLUSIONS: Both BCG and PEL correlate well to nephelometry in sera with zero/low M-spikes.

In the presence of larger M-spikes, PEL correlates poorly to nephelometry or BCG, whereas BCG compares well with nephelometry regardless of M-spike.

[MeSH-major] Bromcresol Green. Multiple Myeloma / diagnosis. Serum Albumin / analysis

Genetic Alliance. consumer health - Multiple myeloma.

MedlinePlus Health Information. consumer health - Multiple Myeloma.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17463172.001).

[ISSN] 0009-9147

[Journal-full-title] Clinical chemistry

[ISO-abbreviation] Clin. Chem.

[Language] eng

[Grant] United States / NCI NIH HHS / CA / CA62242

[Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural

[Publication-country] United States

[Chemical-registry-number] 0 / Indicators and Reagents; 0 / Paraproteins; 0 / Serum Albumin; 8YGN0Y942M / Bromcresol Green

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

The topology of the potential energy landscape (PEL) underlying the dynamics of a two dimensional off-lattice model for a heteropolymer is analyzed for different sequences of amino-acids.

A statistical characterization of the metastable minima and first-order saddles of the PEL highlights structural differences in the landscape of good and bad folding sequences and provides insight on the chain dynamics during folding.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15752597.001).

[ISSN] 0301-4622

[Journal-full-title] Biophysical chemistry

[ISO-abbreviation] Biophys. Chem.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Netherlands

[Chemical-registry-number] 0 / Peptides

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

In order to improve the thermostability of the Penicillium expansum Lipase (PEL), the lipase encoding genes was mutated by site-directed mutagenesis.

A recombinant vector pAO815-ep8-K55R which contain double mutant genes was constructed by overlap extension PCR using the cDNA of a random-mutant lipase ep8 (a single site mutant) as the template and two special primers were used to generate another mutation site K55R.

The recombinant vector was transformed into Pichia pastoris GS115 by electroporation and the recombinant mutant GS-pAO815-ep8- K55R can secret double-mutant lipase PEL-ep8-K55R-GS into the medium when it was induced by Methanol.

The yield of the double-mutant lipase is 508 u/mL, which is 81% that of the wild type lipase PEL-GS (627 u/mL) and 55% that of random-mutant PEL-ep8-GS (924 u/mL).

The specific activity of double-mutant lipase is 2309.1 u/mg, which is similar to random-mutant lipase PEL-ep8-GS and the wild type lipase PEL-GS.

The optimum temperature of the double-mutant lipase is same with the wild type lipase PEL-GS and random-mutant lipase PEL-ep8-GS.

While the Tm of the double-mutant lipase is 41.0 degrees C, 2.3 degrees C higher than the wild type lipase PEL-GS and 0.8% higher than the random-mutant lipase PEL-ep8-GS, indicating that the double-mutant lipase PEL-ep8-K55R-GS has higher thermostability.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17822043.001).

[ISSN] 1000-3061

[Journal-full-title] Sheng wu gong cheng xue bao = Chinese journal of biotechnology

[ISO-abbreviation] Sheng Wu Gong Cheng Xue Bao

[Language] chi

[Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] China

[Chemical-registry-number] 0 / Mutant Proteins; 0 / Recombinant Proteins; EC 3.1.1.3 / Lipase

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

The Kaposi's sarcoma-associated herpesvirus (KSHV/HHV8) is associated with Kaposi's sarcoma (KS) as well as primary effusion lymphomas (PEL).

However, DNA-damaging drugs such as doxorubicin are clinically efficacious against PEL and KS, suggesting that p53 signaling remains intact despite the presence of KSHV.

To investigate the functionality of p53 in PEL, we examined the response of a large number of PEL cell lines to doxorubicin.

Two out of seven (29%) PEL cell lines harbored a mutant p53 allele (BCBL-1 and BCP-1) which led to doxorubicin resistance.

In contrast, all other PEL containing wild-type p53 showed DNA damage-induced cell cycle arrest, p53 phosphorylation, and p53 target gene activation.

Supporting this finding, chemical inhibition of p53 signaling in PEL led to doxorubicin resistance, and chemical activation of p53 by the Hdm2 antagonist Nutlin-3 led to unimpaired induction of p53 target genes as well as growth inhibition and apoptosis.

MedlinePlus Health Information. consumer health - Lymphoma.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. DOXORUBICIN .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Cell. 1993 Nov 19;75(4):817-25 [8242752.001]

[Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]

[Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]

[Cites] Blood. 1995 Oct 1;86(7):2708-14 [7670109.001]

[Cites] Am J Clin Pathol. 1996 Feb;105(2):221-9 [8607449.001]

[Cites] Blood. 1996 Jul 15;88(2):645-56 [8695812.001]

[Cites] Blood. 1996 Oct 1;88(7):2648-54 [8839859.001]

[Cites] J Virol. 1998 Oct;72(10):8309-15 [9733875.001]

[Cites] Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4546-51 [10200299.001]

[Cites] Virology. 1999 Apr 25;257(1):84-94 [10208923.001]

[Cites] Science. 1999 Sep 10;285(5434):1733-7 [10481009.001]

[Cites] Oncogene. 2005 Jan 13;24(3):431-44 [15558026.001]

[Cites] Blood. 2005 Mar 15;105(6):2510-8 [15572586.001]

[Cites] Proc Natl Acad Sci U S A. 2005 Apr 12;102(15):5570-5 [15800047.001]

[Cites] Oncogene. 2005 Apr 18;24(17):2899-908 [15838523.001]

[Cites] Nat Methods. 2005 Apr;2(4):269-76 [15782219.001]

[Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Nov 1;13(3):215-26 [8898666.001]

[Cites] Science. 1996 Nov 8;274(5289):948-53 [8875929.001]

[Cites] J Virol. 1997 Feb;71(2):1629-34 [8995690.001]

[Cites] J Virol. 1997 Aug;71(8):5915-21 [9223481.001]

[Cites] J Clin Invest. 1997 Nov 15;100(10):2606-10 [9366576.001]

[Cites] J Virol. 1998 Feb;72(2):1005-12 [9444993.001]

[Cites] Blood. 1998 Mar 1;91(5):1671-9 [9473233.001]

[Cites] Methods Mol Biol. 2000;132:365-86 [10547847.001]

[Cites] Nature. 1999 Dec 23-30;402(6764):889-94 [10622254.001]

[Cites] Am J Pathol. 2000 Mar;156(3):743-9 [10702388.001]

[Cites] Oncogene. 2000 Mar 30;19(14):1834-42 [10777217.001]

[Cites] J Virol. 2000 Nov;74(21):10187-93 [11024147.001]

[Cites] J Virol. 2000 Dec;74(24):11977-82 [11090200.001]

[Cites] J Virol. 2001 Jan;75(1):429-38 [11119611.001]

[Cites] J Virol. 2001 Jan;75(2):891-902 [11134302.001]

[Cites] J Virol. 2001 Feb;75(4):1798-807 [11160678.001]

[Cites] J Virol. 2001 May;75(10):4843-53 [11312356.001]

[Cites] Oncogene. 1998 Mar;16(11):1429-41 [9525742.001]

[Cites] Science. 1998 Sep 11;281(5383):1674-7 [9733514.001]

[Cites] Science. 1998 Sep 11;281(5383):1677-9 [9733515.001]

[Cites] J Virol. 2005 Jul;79(13):8637-50 [15956606.001]

[Cites] J Virol. 2005 Jul;79(14):9301-5 [15994824.001]

[Cites] Proc Natl Acad Sci U S A. 2006 Feb 7;103(6):1888-93 [16443686.001]

[Cites] Science. 2006 Feb 10;311(5762):856-61 [16469929.001]

[Cites] J Virol. 2006 Mar;80(5):2257-66 [16474133.001]

[Cites] Cancer Res. 2006 Mar 15;66(6):3169-76 [16540668.001]

[Cites] Blood. 2006 May 15;107(10):4122-9 [16439677.001]

[Cites] Blood. 2006 May 15;107(10):4109-14 [16439685.001]

[Cites] Blood. 2006 Aug 1;108(3):993-1000 [16543464.001]

[Cites] J Virol. 2006 Sep;80(18):9017-30 [16940514.001]

[Cites] Arch Ophthalmol. 2006 Sep;124(9):1269-75 [16966622.001]

[Cites] J Biol Chem. 2006 Nov 3;281(44):33036-44 [16905769.001]

[Cites] J Virol. 2001 Jul;75(13):6193-8 [11390621.001]

[Cites] J Virol. 2001 Jul;75(13):6245-8 [11390631.001]

[Cites] J Infect Dis. 2001 Jul 15;184(2):119-26 [11424007.001]

[Cites] Nature. 2001 Aug 30;412(6850):865-6 [11528457.001]

[Cites] Cancer. 2001 Dec 15;92(12):3076-84 [11753987.001]

[Cites] Clin Cancer Res. 2002 Feb;8(2):383-93 [11839653.001]

[Cites] J Virol. 2002 Jun;76(12):6213-23 [12021355.001]

[Cites] Blood. 2003 Mar 15;101(6):2321-7 [12406882.001]

[Cites] Cancer Res. 2003 May 1;63(9):2010-5 [12727810.001]

[Cites] Blood. 2003 May 15;101(10):4115-21 [12531789.001]

[Cites] Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10399-404 [12925741.001]

[Cites] J Clin Oncol. 2003 Nov 1;21(21):3948-54 [14581418.001]

[Cites] Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13303-7 [14595027.001]

[Cites] Oncogene. 2003 Dec 8;22(56):9030-40 [14663481.001]

[Cites] Mol Cancer Res. 2003 Dec;1(14):993-1000 [14707282.001]

[Cites] Science. 2004 Feb 6;303(5659):844-8 [14704432.001]

[Cites] J Virol. 2004 May;78(10):5491-9 [15113928.001]

[Cites] Cancer Res. 2004 Jul 15;64(14):4790-9 [15256448.001]

[Cites] J Virol. 2004 Sep;78(18):10074-85 [15331740.001]

[Cites] Am J Surg Pathol. 2004 Nov;28(11):1401-16 [15489644.001]

[Cites] Methods Mol Biol. 2005;292:449-80 [15507725.001]

[Cites] Cell. 1992 Jun 26;69(7):1237-45 [1535557.001]

[Cites] Cancer Lett. 1993 May 14;69(3):151-60 [8513440.001]

(PMID = 17121789.001).

[ISSN] 0022-538X

[Journal-full-title] Journal of virology

[ISO-abbreviation] J. Virol.

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / CA109232-05; United States / NCI NIH HHS / CA / CA109232-03S1; United States / NCI NIH HHS / CA / R01 CA109232; United States / NCI NIH HHS / CA / R01 CA163217; United States / NCI NIH HHS / CA / R01 CA109232-04; United States / NCI NIH HHS / CA / CA109232-03; United States / NCI NIH HHS / CA / T32 CA009156; United States / NCI NIH HHS / CA / CA009156; United States / NCI NIH HHS / CA / CA700580; United States / NCI NIH HHS / CA / CA109232-01; United States / NIDCR NIH HHS / DE / R01 DE018304; United States / NCI NIH HHS / CA / CA109232-02; United States / NCI NIH HHS / CA / R01 CA109232-05; United States / NCI NIH HHS / CA / R01 CA109232-02; United States / NCI NIH HHS / CA / CA109232; United States / NCI NIH HHS / CA / R01 CA109232-01; United States / NCI NIH HHS / CA / R01 CA109232-03S1; United States / NCI NIH HHS / CA / R01 CA109232-03; United States / NCI NIH HHS / CA / CA109232-04

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / Imidazoles; 0 / Piperazines; 0 / Tumor Suppressor Protein p53; 0 / nutlin 3; 80168379AG / Doxorubicin; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2

[Other-IDs] NLM/ PMC1797584

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Contrary to mammalian DNA, which is thought to contain only 5-methylcytosine (m5C), bacterial DNA contains two additional methylated bases, namely N6-methyladenine (m6A), and N4-methylcytosine (m4C).

However, if the main function of m5C and m4C in bacteria is protection against restriction enzymes, the roles of m6A are multiple and include, for example, the regulation of virulence and the control of many bacterial DNA functions such as the replication, repair, expression and transposition of DNA.

Interestingly, even if adenine methylation is usually considered a bacterial DNA feature, the presence of m6A has been found in protist and plant DNAs.

Furthermore, indirect evidence suggests the presence of m6A in mammal DNA, raising the possibility that this base has remained undetected due to the low sensitivity of the analytical methods used.

This highlights the importance of considering m6A as the sixth element of DNA.

HAL archives ouvertes. Full text from .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] Copyright 2006 Wiley Periodicals, Inc.

[Cites] Mol Cell Biol. 1981 Jul;1(7):600-8 [9279374.001]

[Cites] J Androl. 1997 Jul-Aug;18(4):372-7 [9283949.001]

[Cites] J Bacteriol. 1997 Sep;179(18):5869-77 [9294447.001]

[Cites] Science. 1999 May 7;284(5416):967-70 [10320378.001]

[Cites] Nat Biotechnol. 1999 Jun;17(6):517 [10385302.001]

[Cites] J Biol Chem. 1999 Jul 9;274(28):19538-44 [10391886.001]

[Cites] J Bacteriol. 1999 Sep;181(17):5135-9 [10464180.001]

[Cites] Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11578-83 [10500219.001]

[Cites] J Bacteriol. 1952 Oct;64(4):557-69 [12999684.001]

[Cites] J Bacteriol. 1953 Feb;65(2):113-21 [13034700.001]

[Cites] Biochem J. 1958 Apr;68(4):627-36 [13522672.001]

[Cites] Biochim Biophys Acta. 1965 Mar 15;95:513-5 [14342545.001]

[Cites] J Biol Chem. 2004 Dec 10;279(50):52075-81 [15456775.001]

[Cites] Curr Opin Microbiol. 2005 Apr;8(2):154-60 [15802246.001]

[Cites] Mol Microbiol. 2000 Mar;35(5):1168-79 [10712697.001]

[Cites] J Bacteriol. 2000 Jun;182(12):3482-9 [10852881.001]

[Cites] Virology. 2000 Jul 5;272(2):409-16 [10873785.001]

[Cites] Hum Mol Genet. 2000 Oct;9(16):2395-402 [11005794.001]

[Cites] Biochem Biophys Res Commun. 2000 Oct 5;276(3):1261-4 [11027620.001]

[Cites] Int Microbiol. 2000 Sep;3(3):139-46 [11032305.001]

[Cites] Nat Rev Mol Cell Biol. 2001 Feb;2(2):147-51 [11252956.001]

[Cites] J Bacteriol. 2001 May;183(10):3065-75 [11325934.001]

[Cites] Biochem Biophys Res Commun. 2001 Jul 20;285(3):800-5 [11453663.001]

[Cites] J Am Chem Soc. 2001 Feb 7;123(5):976-7 [11456633.001]

[Cites] Biochemistry (Mosc). 2001 Jul;66(7):753-62 [11563955.001]

[Cites] Infect Immun. 2001 Dec;69(12):7197-204 [11705888.001]

[Cites] Infect Immun. 2001 Dec;69(12):7610-5 [11705940.001]

[Cites] Nucleic Acids Res. 2002 Mar 15;30(6):1364-70 [11884634.001]

[Cites] J Cell Sci. 2002 Jun 1;115(Pt 11):2381-8 [12006622.001]

[Cites] Mol Microbiol. 2002 Aug;45(3):673-95 [12139615.001]

[Cites] EMBO J. 2002 Sep 16;21(18):4969-77 [12234936.001]

[Cites] Cancer Res. 2002 Dec 1;62(23):6791-5 [12460886.001]

[Cites] FEBS Lett. 2002 Dec 18;532(3):367-72 [12482594.001]

[Cites] Plant J. 2003 Nov;36(4):550-64 [14617085.001]

[Cites] Biochem Biophys Res Commun. 2004 Feb 6;314(2):476-82 [14733930.001]

[Cites] Genes Genet Syst. 2003 Dec;78(6):391-8 [14973340.001]

[Cites] Nature. 1970 Mar 7;225(5236):948-9 [4391887.001]

[Cites] Biochem J. 1972 Jun;128(1):133-8 [5085550.001]

[Cites] J Cell Biol. 1973 Mar;56(3):697-701 [4631666.001]

[Cites] Biochim Biophys Acta. 1974 Nov 20;374(1):1-11 [4429738.001]

[Cites] Nature. 1975 May 15;255(5505):197-200 [1143315.001]

[Cites] Proc Natl Acad Sci U S A. 1976 Nov;73(11):3923-7 [1069277.001]

[Cites] J Bacteriol. 1978 Sep;135(3):1156-7 [99431.001]

[Cites] Proc Natl Acad Sci U S A. 1978 Oct;75(10):4992-6 [105360.001]

[Cites] Biochim Biophys Acta. 1979 Jun 20;563(1):72-81 [497215.001]

[Cites] Gene. 1983 May-Jun;22(2-3):139-56 [6307815.001]

[Cites] J Bacteriol. 1984 Nov;160(2):586-90 [6094478.001]

[Cites] Nucleic Acids Res. 1985 Feb 25;13(4):1399-412 [4000939.001]

[Cites] J Virol. 1985 Oct;56(1):320-4 [2993662.001]

[Cites] J Mol Biol. 1986 May 20;189(2):371-5 [3489102.001]

[Cites] Mol Cell Biol. 1986 Jul;6(7):2364-70 [3023930.001]

[Cites] J Gen Microbiol. 1986 Nov;132(11):3055-9 [3114425.001]

[Cites] Biochem Biophys Res Commun. 1987 Sep 30;147(3):1082-7 [3663209.001]

[Cites] Trends Genet. 1989 May;5(5):139-43 [2667217.001]

[Cites] Mol Cell Biol. 1989 Jun;9(6):2598-605 [2548083.001]

[Cites] Mol Cell Biol. 1989 Nov;9(11):4759-66 [2689864.001]

[Cites] Cell. 1990 Sep 7;62(5):981-9 [2203541.001]

[Cites] Biochem Cell Biol. 1990 Jun;68(6):944-8 [2168719.001]

[Cites] Eur J Biochem. 1990 Dec 12;194(2):513-20 [1702711.001]

[Cites] Exp Parasitol. 1991 May;72(4):339-44 [1851101.001]

[Cites] Nucleic Acids Res. 1992 Apr 11;20(7):1483-6 [1579439.001]

[Cites] Nucleic Acids Res. 1992 Oct 25;20(20):5351-6 [1437552.001]

[Cites] J Mol Biol. 1994 Jan 14;235(2):472-85 [8289276.001]

[Cites] Cell. 1994 Feb 11;76(3):577-88 [7906204.001]

[Cites] Gene. 1994 Dec 30;151(1-2):89-95 [7828910.001]

[Cites] Plant J. 1995 Feb;7(2):221-33 [7704046.001]

[Cites] Proc Natl Acad Sci U S A. 1996 Feb 6;93(3):1210-4 [8577742.001]

[Cites] Transgenic Res. 1995 Sep;4(5):324-31 [8589735.001]

[Cites] Gene. 1997 May 6;190(2):237-44 [9197539.001]

[Cites] J Bacteriol. 1997 Jul;179(13):4254-63 [9209041.001]

[Cites] Trends Genet. 1997 Aug;13(8):335-40 [9260521.001]

(PMID = 16479578.001).

[ISSN] 0265-9247

[Journal-full-title] BioEssays : news and reviews in molecular, cellular and developmental biology

[ISO-abbreviation] Bioessays

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review

[Publication-country] United States

[Chemical-registry-number] 9007-49-2 / DNA; JAC85A2161 / Adenine; W7IBY2BGAX / 6-methyladenine

[Number-of-references] 91

[Other-IDs] NLM/ HALMS390682; NLM/ PMC2754416

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Primary effusion lymphoma (PEL) is a very rare subgroup of B-cell lymphomas presenting as pleural, peritoneal and pericardial neoplastic effusions in the absence of a solid tumor mass or recognizable nodal involvement.

There is strong evidence that Kaposi's sarcoma-associated herpesvirus (KSHV) is a causal agent of PEL.

PEL tumor cells are latently infected by KSHV with consistent expression of several viral proteins and microRNAs that can affect cellular proliferation, differentiation and survival.

The most relevant data on pathogenesis and biology of KSHV have been provided by studies on PEL-derived cell lines.

Fourteen continuous cell lines have been established from the malignant effusions of patients with AIDS-associated and non-AIDS-associated PEL.

The PEL cell lines display unique features and are clearly distinct from other lymphoma cell lines.

PEL cell lines represent an indispensable tool for the understanding of KSHV biology and its impact on the clinical manifestation of PEL.

Studies on PEL cell lines have shown that a number of viral genes, expressed during latency or lytic life cycle, have effects on cell binding, proliferation, angiogenesis and inflammation.

Also, PEL cell lines are important model systems for the study of the disorder of PEL including the lack of invasive or destructive growth patterns and the peculiar propensity of PEL to involve body cavity surfaces.

Genetic Alliance. consumer health - Primary effusion lymphoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Blood. 2000 Aug 15;96(4):1599-601 [10942415.001]

[Cites] Int J Cancer. 1997 Nov 14;73(4):562-9 [9389573.001]

[Cites] Blood. 1998 Mar 1;91(5):1671-9 [9473233.001]

[Cites] J Virol. 1998 Jun;72(6):5182-8 [9573290.001]

[Cites] Trends Genet. 1998 Apr;14(4):144-50 [9594662.001]

[Cites] J Gen Virol. 1998 Jul;79 ( Pt 7):1573-91 [9680119.001]

[Cites] Adv Cancer Res. 1998;75:57-86 [9709807.001]

[Cites] Br J Haematol. 1998 Sep;102(4):1081-9 [9734661.001]

[Cites] Leukemia. 1998 Oct;12(10):1507-17 [9766492.001]

[Cites] Arch Pathol Lab Med. 1999 Mar;123(3):257-60 [10086517.001]

[Cites] Leukemia. 1999 Apr;13(4):634-40 [10214873.001]

[Cites] Adv Cancer Res. 1999;76:121-60 [10218100.001]

[Cites] Trends Microbiol. 1999 May;7(5):196-200 [10354594.001]

[Cites] Blood. 1999 Jun 15;93(12):4034-43 [10361100.001]

[Cites] Adv Virus Res. 1999;52:139-232 [10384236.001]

[Cites] J Med Virol. 1999 Aug;58(4):394-401 [10421407.001]

[Cites] J Infect Dis. 1999 Sep;180(3):824-8 [10438372.001]

[Cites] J Exp Med. 1999 Oct 4;190(7):1025-32 [10510092.001]

[Cites] Blood. 1999 Oct 15;94(8):2871-9 [10515891.001]

[Cites] Cancer Res. 1999 Oct 1;59(19):4984-9 [10519412.001]

[Cites] J Virol. 2005 Jan;79(2):1244-51 [15613351.001]

[Cites] Leuk Lymphoma. 2005 Mar;46(3):415-9 [15621832.001]

[Cites] J Mol Diagn. 2005 Feb;7(1):17-27 [15681470.001]

[Cites] Blood. 2005 Mar 15;105(6):2510-8 [15572586.001]

[Cites] Leuk Res. 2005 May;29(5):545-55 [15755507.001]

[Cites] Am J Surg Pathol. 2005 May;29(5):647-52 [15832089.001]

[Cites] Blood. 2000 Oct 1;96(7):2537-42 [11001908.001]

[Cites] J Virol. 2000 Nov;74(21):10187-93 [11024147.001]

[Cites] Adv Cancer Res. 2001;80:115-46 [11034542.001]

[Cites] J Virol. 2001 Feb;75(4):1857-63 [11160684.001]

[Cites] J Virol. 2001 Mar;75(6):2938-45 [11222719.001]

[Cites] Int J Hematol. 2002 Aug;76(2):165-72 [12215016.001]

[Cites] Blood. 2003 May 15;101(10):4115-21 [12531789.001]

[Cites] Oncogene. 2003 May 29;22(22):3371-85 [12776188.001]

[Cites] Leuk Lymphoma. 2003 May;44(5):833-40 [12802923.001]

[Cites] Lab Invest. 2003 Jun;83(6):913-6 [12808126.001]

[Cites] J Cell Sci. 2003 Sep 15;116(Pt 18):3721-8 [12890756.001]

[Cites] Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10399-404 [12925741.001]

[Cites] J Clin Oncol. 2003 Nov 1;21(21):3948-54 [14581418.001]

[Cites] J Exp Med. 2004 Apr 5;199(7):993-1003 [15067035.001]

[Cites] Am J Surg Pathol. 2004 Nov;28(11):1401-16 [15489644.001]

[Cites] Blood. 1989 Feb 15;73(3):792-9 [2537119.001]

[Cites] Am J Clin Pathol. 1990 Aug;94(2):170-5 [2371971.001]

[Cites] Blood. 1993 Jul 1;82(1):247-61 [8100721.001]

[Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]

[Cites] Blood. 1995 Oct 1;86(7):2708-14 [7670109.001]

[Cites] Nat Med. 1996 Mar;2(3):342-6 [8612236.001]

[Cites] J Exp Med. 1996 May 1;183(5):2385-90 [8642350.001]

[Cites] Blood. 1996 Jun 15;87(12):4937-43 [8652805.001]

[Cites] Am J Pathol. 1996 Jul;149(1):53-7 [8686762.001]

[Cites] Cell. 1996 Jun 14;85(6):817-27 [8681377.001]

[Cites] Leukemia. 1996 Jul;10(7):1237-40 [8684008.001]

[Cites] Blood. 1996 Jul 15;88(2):645-56 [8695812.001]

[Cites] Nature. 1996 Aug 1;382(6590):410 [8684480.001]

[Cites] Br J Haematol. 1996 Sep;94(3):533-43 [8790156.001]

[Cites] Blood. 1996 Oct 1;88(7):2648-54 [8839859.001]

[Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Nov 1;13(3):215-26 [8898666.001]

[Cites] Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14862-7 [8962146.001]

[Cites] N Engl J Med. 1997 Jan 16;336(3):163-71 [8988896.001]

[Cites] EMBO J. 1997 May 15;16(10):2794-804 [9184224.001]

[Cites] Br J Haematol. 1997 Jun;97(3):515-22 [9207392.001]

[Cites] J Virol. 1997 Aug;71(8):5915-21 [9223481.001]

[Cites] J Biol Chem. 1997 Aug 1;272(31):19625-31 [9235971.001]

[Cites] Radiology. 1997 Nov;205(2):459-63 [9356629.001]

[Cites] Virology. 1997 Nov 10;238(1):22-9 [9375005.001]

[Cites] J Clin Oncol. 2005 Jul 1;23(19):4372-80 [15994147.001]

[Cites] J Pathol. 2006 Jan;208(2):187-98 [16362980.001]

[Cites] EMBO Rep. 2006 Jan;7(1):114-9 [16311516.001]

[Cites] Blood. 2006 Jan 15;107(2):725-32 [16160006.001]

[Cites] Mol Cell Biol. 2006 Mar;26(6):2430-40 [16508017.001]

[Cites] Blood. 2006 Apr 15;107(8):3295-302 [16380446.001]

[Cites] Diagn Cytopathol. 2006 May;34(5):335-47 [16604559.001]

[Cites] J Pathol. 2006 Aug;209(4):464-73 [16741895.001]

[Cites] Curr Top Microbiol Immunol. 2007;312:185-209 [17089798.001]

[Cites] Acta Haematol. 2007;117(3):129-31 [17135725.001]

[Cites] Acta Haematol. 2007;117(3):132-44 [17135726.001]

[Cites] Leuk Res. 2007 Sep;31(9):1285-92 [17368758.001]

[Cites] Cancer. 2007 Aug 25;111(4):224-33 [17554754.001]

[Cites] PLoS Pathog. 2007 Sep 7;3(9):1348-60 [17907806.001]

[Cites] Br J Haematol. 2008 Jan;140(1):13-24 [17991301.001]

[Cites] Blood. 2008 Jan 1;111(1):320-7 [17890449.001]

[Cites] J Cell Sci. 2008 Feb 15;121(Pt 4):450-7 [18211958.001]

[Cites] Blood. 2009 Feb 5;113(6):1213-24 [18955561.001]

[Cites] Lancet Oncol. 2009 Apr;10(4):321-2 [19350698.001]

[Cites] Blood. 1999 Dec 15;94(12):4247-54 [10590069.001]

[Cites] J Clin Virol. 2000 May;16(3):215-24 [10738140.001]

[Cites] Leuk Lymphoma. 2000 Jul;38(3-4):401-9 [10830748.001]

[Cites] J Virol. 2000 Jul;74(13):6207-12 [10846108.001]

[Cites] Leukemia. 2000 Jul;14(7):1301-9 [10914556.001]

[Cites] J Immunol. 2000 Aug 15;165(4):2077-83 [10925292.001]

(PMID = 20051807.001).

[ISSN] 1473-5571

[Journal-full-title] AIDS (London, England)

[ISO-abbreviation] AIDS

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / R01 CA068939; United States / NCI NIH HHS / CA / R01 CA103646; United States / NCI NIH HHS / CA / R01CA068939; United States / NCI NIH HHS / CA / R01CA103646

[Publication-type] Editorial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review

[Publication-country] England

[Chemical-registry-number] 0 / Cytokines; 0 / Vascular Endothelial Growth Factor A

[Other-IDs] NLM/ NIHMS492494; NLM/ PMC3740588

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Primary effusion lymphoma (PEL) is very rare type of non-Hodgkin's lymphoma (NHL) usually confined to the body cavities such as the pleural space, pericardium, and peritoneum.

PEL is a human herpes virus-8 (HHV-8)-associated lymphoma and commonly observed in human immunodeficiency virus (HIV)-infected patients.

However, HIV-infected patients are extremely fewer in Japan in comparison with those in Western countries; PEL is usually not associated with HIV infection in Japan.

This report presents seven Japanese cases of PEL.

In situ hybridization revealed that the PEL cells were negative for EBV in all cases.

An immunocytological analysis showed that only one case was positive for HHV-8, and PEL cells were positive for CD20 in all cases.

However, the cytomorphological features of PEL cells showed large cell size, abundant basophilic cytoplasm, coarse chromatin, and occasional binucleated or multinucleated cells, similar to a large cell immunoblastic and anaplastic large cell lymphoma, indicating that the cytomorphological characteristics of PE cells in Giemsa and Papanicolaou stain were consistent with those reported abroad.

The prognosis for PEL in these cases was poor, but the survival time was variable ranging from 1 month to 54 months, and was different from that of Western cases.

No p16/CDKN2A expression was observed, and one case showed PEL cells with a BLIMP1 mutation.

Genetic Alliance. consumer health - Primary effusion lymphoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19217041.001).

[ISSN] 1097-0339

[Journal-full-title] Diagnostic cytopathology

[ISO-abbreviation] Diagn. Cytopathol.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Biochemical properties of pectate lyases produced by three different Bacillus strains isolated from fermenting cocoa beans and characterization of their cloned genes.

In this study, we characterized three extracellular pectate lyases (Pels) produced by bacilli isolated from fermenting cocoa beans.

These enzymes, named Pel-22, Pel-66, and Pel-90, were synthesized by Bacillus pumilus BS22, Bacillus subtilis BS66, and Bacillus fusiformis BS90, respectively.

Pel-22 had a low specific activity compared with the other two enzymes.

However, it displayed high affinity for the substrate, about 2.5-fold higher than those of Pel-66 and Pel-90.

The optimum pHs were 7.5 for Pel-22 and 8.0 for Pel-66 and Pel-90.

A synergistic effect was observed between Pel-22 and Pel-66 and between Pel-22 and Pel-90, but not between Pel-90 and Pel-66.

The Pels were also strongly active on highly methylated pectins (up to 60% for Pel-66 and Pel-90 and up to 75% for Pel-22).

Fe(2+) was found to be a better cofactor than Ca(2+) for Pel-22 activity, while Ca(2+) was the best cofactor for Pel-66 and Pel-90.

The amino acid sequences deduced from the cloned genes showed the characteristics of Pels belonging to Family 1.

The pel-66 and pel-90 genes appear to be very similar, but they are different from the pel-22 gene.

The characterized enzymes form two groups, Pel-66/Pel-90 and Pel-22; members of the different groups might cooperate to depolymerize pectin during the fermentation of cocoa beans.

Hazardous Substances Data Bank. IRON, ELEMENTAL .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Bacteriol. 1992 Mar;174(6):2039-42 [1548242.001]

[Cites] Biochimie. 1990 Sep;72(9):689-95 [2126210.001]

[Cites] Mol Plant Microbe Interact. 1995 Mar-Apr;8(2):207-17 [7756691.001]

[Cites] Nat Struct Biol. 1994 Oct;1(10):717-23 [7634076.001]

[Cites] Annu Rev Microbiol. 1996;50:213-57 [8905080.001]

[Cites] J Bacteriol. 1996 Dec;178(24):7187-96 [8955401.001]

[Cites] J Bacteriol. 1997 Apr;179(8):2503-11 [9098045.001]

[Cites] J Bacteriol. 1997 Dec;179(23):7321-30 [9393696.001]

[Cites] Appl Environ Microbiol. 1998 Apr;64(4):1477-83 [9546184.001]

[Cites] J Bacteriol. 1999 Mar;181(5):1652-63 [10049400.001]

[Cites] Biochim Biophys Acta. 1999 Apr 19;1427(2):145-54 [10216231.001]

[Cites] J Bacteriol. 1999 Jun;181(12):3705-9 [10368144.001]

[Cites] Biosci Biotechnol Biochem. 1999 Jun;63(6):998-1005 [10427684.001]

[Cites] J Biotechnol. 2006 Feb 10;121(3):390-401 [16168510.001]

[Cites] Microbiology. 2006 Mar;152(Pt 3):617-25 [16514142.001]

[Cites] Mol Plant Microbe Interact. 2006 Mar;19(3):280-7 [16570658.001]

[Cites] Biotechnol Lett. 2007 Mar;29(3):405-10 [17237974.001]

[Cites] Nucleic Acids Res. 2009 Jan;37(Database issue):D233-8 [18838391.001]

[Cites] Biosci Biotechnol Biochem. 2009 Feb;73(2):268-73 [19202269.001]

[Cites] Microbiology. 2000 Jan;146 ( Pt 1):89-95 [10658655.001]

[Cites] Biochem J. 2001 Apr 1;355(Pt 1):155-65 [11256960.001]

[Cites] J Biol Chem. 2004 Mar 5;279(10):9139-45 [14670977.001]

[Cites] Appl Microbiol Biotechnol. 2004 May;64(4):560-7 [14673544.001]

[Cites] Crit Rev Food Sci Nutr. 2004;44(4):205-21 [15462126.001]

[Cites] Arch Biochem Biophys. 1968 Feb;123(2):298-306 [5642600.001]

[Cites] Nature. 1970 Aug 15;227(5259):680-5 [5432063.001]

[Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]

[Cites] J Bacteriol. 1984 Sep;159(3):825-31 [6090392.001]

[Cites] FEBS Lett. 1993 Dec 13;335(3):319-26 [8262178.001]

(PMID = 20543060.001).

[ISSN] 1098-5336

[Journal-full-title] Applied and environmental microbiology

[ISO-abbreviation] Appl. Environ. Microbiol.

[Language] eng

[Databank-accession-numbers] GENBANK/ GU576909/ GU576910/ GU576911

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Cations, Divalent; 0 / Coenzymes; 0 / DNA, Bacterial; 0 / Pectins; 0 / Recombinant Proteins; 9046-38-2 / polygalacturonic acid; E1UOL152H7 / Iron; EC 4.2.2.- / Polysaccharide-Lyases; EC 4.2.2.2 / pectate lyase; SY7Q814VUP / Calcium

[Other-IDs] NLM/ PMC2916476

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Value of elastin staining in the assessment of peritoneal implants associated with ovarian serous borderline tumours.

AIMS: To determine whether elastin stains aid in classifying peritoneal implants associated with ovarian serous borderline tumours (SBT).

Elastin stains were performed using histochemical and immunohistochemical methods to demonstrate the peritoneal elastic lamina (PEL), and evaluated with regard to assessment of the subtype of implant.

The elastin stains demonstrated the PEL in most anatomical sites other than the omentum and the bladder and were considered helpful in 44/80 (55%) cases.

The staining was non-contributory in most of the remaining biopsies, because the PEL was not identified.

CONCLUSIONS: Demonstration of the PEL using elastin stains can be useful in the subclassification of implants associated with ovarian SBT and is of most value in confirming the superficial distribution of non-invasive lesions.

However, evaluation is limited by the absence of a defined elastic layer in a proportion of biopsy specimens, possibly reflecting their superficial location, as well as absence of a distinct PEL in sites such as the omentum.

[MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Immunohistochemistry. Middle Aged. Peritoneal Neoplasms / diagnosis. Peritoneal Neoplasms / metabolism. Peritoneal Neoplasms / secondary. Predictive Value of Tests

MedlinePlus Health Information. consumer health - Ovarian Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17727474.001).

[ISSN] 0309-0167

[Journal-full-title] Histopathology

[ISO-abbreviation] Histopathology

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

[Chemical-registry-number] 9007-58-3 / Elastin

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Primary effusion lymphoma (PEL) was initially designated as a body-cavity-based lymphoma and recognized as a distinct clinical entity without a contiguous tumor mass.

PEL was first reported in patients with acquired immunodeficiency syndrome (AIDS) and the distinctive feature of PEL originally reported as a B-cell neoplasm characterized by infection of the tumor cells by human herpes virus 8 (HHV-8).

However, there have recently been several reports of PEL in patients without human immunodeficiency virus (HIV) or HHV-8 infection.

[MeSH-major] Antigens, CD4 / biosynthesis. DNA-Binding Proteins / genetics. Gene Rearrangement. Herpesvirus 8, Human / genetics. Lymphoma, Primary Effusion / genetics. Lymphopenia / therapy. T-Lymphocytes / metabolism

[MeSH-minor] Aged. Antineoplastic Agents / pharmacology. Dyspnea / diagnosis. HIV Infections / diagnosis. Humans. Immunophenotyping. Male. Pericardial Effusion

Genetic Alliance. consumer health - Primary effusion lymphoma.

Genetic Alliance. consumer health - T-Lymphocytopenia.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18166773.001).

[ISSN] 1592-8721

[Journal-full-title] Haematologica

[ISO-abbreviation] Haematologica

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Italy

[Chemical-registry-number] 0 / Antigens, CD4; 0 / Antineoplastic Agents; 0 / BCL6 protein, human; 0 / DNA-Binding Proteins

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Primary effusion lymphomas (PEL) form a subset of AIDS-related lymphomas and usually have a poor prognosis.

Although Kaposi's sarcoma-associated herpes virus (KSHV) is often associated with PEL, very little is known about the exact mechanisms or causative effects of these associations.

We investigated the chromosomal imbalances in six KSHV-positive PEL cell lines using comparative genomic hybridization analysis.

The recurrent nature of the gains found in these chromosomal regions suggests that these imbalances play roles in the pathogenesis of PEL.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Blood. 2003 Mar 1;101(5):1956-61 [12406869.001]

[Cites] J Infect Dis. 1999 Nov;180(5):1466-76 [10515805.001]

[Cites] Genes Chromosomes Cancer. 2005 Nov;44(3):305-19 [16075461.001]

[Cites] J Clin Virol. 2000 May;16(3):215-24 [10738140.001]

[Cites] Arch Pathol Lab Med. 2000 Jun;124(6):824-6 [10835513.001]

[Cites] Recent Results Cancer Res. 2002;159:27-37 [11785841.001]

[Cites] Hematol J. 2001;2(3):172-9 [11920242.001]

[Cites] Leuk Lymphoma. 2002 Mar;43(3):595-601 [12002764.001]

[Cites] AIDS Patient Care STDS. 2004 Feb;18(2):67-73 [15006181.001]

[Cites] J Exp Med. 2004 Apr 5;199(7):993-1003 [15067035.001]

[Cites] Cancer Res. 2004 Jun 15;64(12):4064-8 [15205312.001]

[Cites] J Med Genet. 1999 Jul;36(7):511-7 [10424810.001]

(PMID = 17116491.001).

[ISSN] 0165-4608

[Journal-full-title] Cancer genetics and cytogenetics

[ISO-abbreviation] Cancer Genet. Cytogenet.

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / R01 CA096512; United States / NCI NIH HHS / CA / R01 CA096512-02; United States / NCI NIH HHS / CA / R01 CA096512-03; United States / NCI NIH HHS / CA / R01 CA124332; United States / NCI NIH HHS / CA / CA096512-01A2; United States / NCI NIH HHS / CA / CA096512-02; United States / NCI NIH HHS / CA / R01 CA124332-01A2; United States / NCI NIH HHS / CA / R01 CA096512-01A2; United States / NCI NIH HHS / CA / R01 CA096512-04; United States / NCI NIH HHS / CA / R01 CA132637

[Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural

[Publication-country] United States

[Other-IDs] NLM/ NIHMS165930; NLM/ PMC2799290

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Kaposi sarcoma-associated herpesvirus is associated with two lymphoproliferative disorders, primary effusion lymphoma (PEL) and Castleman disease.

In PEL, Kaposi sarcoma-associated herpesvirus is present in a latent form expressing only few viral genes.

To study the role of vIRF-3 in PEL lymphomagenesis, we analyzed the interaction of vIRF-3 with cellular proteins.

The vIRF-3 and MM-1alpha interaction was also demonstrated by glutathione S-transferase pulldown assay and coimmunoprecipitation of endogenous vIRF-3 and MM-1alpha in PEL-derived cell lines.

Overexpression of vIRF-3 enhanced the c-Myc-dependent transcription of the gene cdk4.

Furthermore, the recruitment of vIRF-3 to the cdk4 promoter and the elevated levels of the histone H3 acetylation suggest the direct involvement of vIRF-3 in the activation of c-Myc-mediated transcription.

These findings indicate that vIRF-3 can effectively stimulate c-Myc function in PEL cells and consequently contribute to de-regulation of B-cell growth and differentiation.

[MeSH-minor] Cell Line, Tumor. Gene Library. Humans. Two-Hybrid System Techniques

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17728244.001).

[ISSN] 0021-9258

[Journal-full-title] The Journal of biological chemistry

[ISO-abbreviation] J. Biol. Chem.

[Language] eng

[Grant] United States / NCI NIH HHS / CA / R01CA76946

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Interferon Regulatory Factor-3; 0 / Interferon Regulatory Factors; 0 / Proto-Oncogene Proteins c-myc; 0 / Viral Proteins; 0 / viral interferon regulatory factors

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

In a recently concluded study, we identified Kaposi's sarcoma-associated herpesvirus (KSHV)-infected cells derived from primary effusion lymphoma (PEL) to overexpress vascular endothelial growth factor (VEGF) that had the propensity to mediate tubule formation on a Matrigel, an indicator of angiogenesis.

The objective of this study was to determine the receptor molecules that mediate the tubule formation induced by the supernatant derived from KSHV-infected PEL cells.

METHODS: The identity of receptor(s) that play a role in mediating tubule formation driven by PEL supernatant was determined by the classical in vitro angiogenesis assay conducted on a Matrigel.

RESULTS: RGD peptides, antibodies, and siRNA specific to beta1 integrins significantly lowered the ability of the PEL supernatants to induce tubule formation by endothelial cells. beta1 Integrins mediated tubule formation to comparable levels in endothelial cells that were incubated with supernatants derived from uninduced or TPA-induced PEL cells.

CONCLUSION: We report for the first time a critical role for beta1 integrins in angiogenesis supported by the supernatant from KSHV-infected PEL cells.

[MeSH-minor] B-Lymphocytes / virology. Cell Line, Transformed. Cell Transformation, Viral. Cells, Cultured. Collagen. Drug Combinations. Endothelium, Vascular / cytology. Herpesviridae Infections / virology. Humans. Laminin. Proteoglycans. Vascular Endothelial Growth Factor A / metabolism

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] Copyright 2007 S. Karger AG, Basel.

(PMID = 17460413.001).

[ISSN] 1423-0100

[Journal-full-title] Intervirology

[ISO-abbreviation] Intervirology

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Switzerland

[Chemical-registry-number] 0 / Antigens, CD29; 0 / Culture Media, Conditioned; 0 / Drug Combinations; 0 / Laminin; 0 / Proteoglycans; 0 / Vascular Endothelial Growth Factor A; 119978-18-6 / matrigel; 9007-34-5 / Collagen

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

The second region was the polyelectrolyte (PEL) coated surface that promoted protein and cell immobilization.

The difference in surface functionality between the PEL region and background PEG microstructures resulted in simple patterning of biomolecules.

Fluorescein isothiocyanate-tagged bovine serum albumin, E. coli expressing green fluorescence protein (GFP), and fibroblast cells were successfully bound to the exposed PEL surfaces at micron scale.

Compared with the simple adsorption of protein, fluorescence intensity was dramatically improved (by about six-fold) on the PEL-modified surfaces.

Although animal cell patterning is prerequisite for adhesive protein layer to survive on desired area, the PEL surface without adhesive proteins provides affordable microenvironment for cells.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17400439.001).

[ISSN] 0956-5663

[Journal-full-title] Biosensors & bioelectronics

[ISO-abbreviation] Biosens Bioelectron

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Dimethylpolysiloxanes; 0 / Electrolytes; 0 / Proteins; 0 / Silicones; 30IQX730WE / Polyethylene Glycols; 63148-62-9 / baysilon

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Pelargonidin (PEL), a common anthocyanidin with estrogenic activity, was tested in HL-60 cells for its genotoxicity and possible antigenotoxic effects against 4-nitroquinoline 1-oxide (NQO), a potent mutagen and carcinogen which induces oxidative stress.

To take into account potential interactions between phytochemicals within normal human nutrition, we evaluated a combination of PEL with the nonestrogenic phytochemical chlorogenic acid (CLA), one of the most abundant polyphenols in the human diet.

PEL (< or = 2 microM) and CLA (< or = 800 microM) were nongenotoxic in the micronucleus test.

We observed significant antigenotoxic effects against NQO with both compounds, but no additive interaction of PEL and CLA.

Flow cytometric analysis of oxidative stress revealed significant protection against NQO-induced oxidative stress by PEL, CLA, and their combination.

Furthermore, PEL and CLA prevented the NQO-induced reduction in GSH level.

In conclusion, the phytoestrogen PEL revealed antioxidative and antigenotoxic properties in HL-60 cells, but no significant additive interaction with the abundant nutritional polyphenol CLA under the tested conditions.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17579891.001).

[ISSN] 1613-4125

[Journal-full-title] Molecular nutrition & food research

[ISO-abbreviation] Mol Nutr Food Res

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Germany

[Chemical-registry-number] 0 / Anthocyanins; 0 / Antimutagenic Agents; 0 / Mutagens; 0 / Phytoestrogens; 318ADP12RI / Chlorogenic Acid; 56-57-5 / 4-Nitroquinoline-1-oxide; 7690-51-9 / pelargonidin

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Primary effusion lymphoma (PEL) is a rare type of lymphoma related to herpesvirus-8 (HHV-8), and considered an AIDS-defining condition.

The authors describe a case of PEL with cardiac involvement occurring in an HIV-positive patient treated with HAART and chemotherapy, who achieved complete remission and long survival.

[MeSH-major] Antiretroviral Therapy, Highly Active. HIV Infections / complications. HIV Infections / drug therapy. HIV Long-Term Survivors. Heart Neoplasms / secondary. Lymphoma, Primary Effusion / complications. Lymphoma, Primary Effusion / diagnosis

Genetic Alliance. consumer health - Primary effusion lymphoma.

Genetic Alliance. consumer health - HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS.

MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18845471.001).

[ISSN] 1386-6532

[Journal-full-title] Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology

[ISO-abbreviation] J. Clin. Virol.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Netherlands

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Primary effusion lymphoma (PEL) is an aggressive neoplasm caused by Kaposi sarcoma-associated herpesvirus/human herpesvirus 8 (KSHV/HHV-8) infection.

Hybrid liposomes (HL), composed of dimyristoylphosphatidylcholine (DMPC) and polyoxyethylene dodecyl ether, inhibited PEL cell proliferation and induced apoptosis in vitro.

Intraperitoneal inoculation of the BCBL-1 PEL cell line into NOD/Scid/Jak3 deficient mice induced massive ascites, which were inhibited by HL21 without significant systemic toxicity in the mice.

These results suggest that HL21 is an effective and attractive reagent for PEL treatment.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] Copyright 2009 Elsevier Ltd. All rights reserved.

(PMID = 20074798.001).

[ISSN] 1873-5835

[Journal-full-title] Leukemia research

[ISO-abbreviation] Leuk. Res.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Liposomes; 0 / polyoxyethylene-10-dodecyl ether; 30IQX730WE / Polyethylene Glycols; EC 2.7.10.2 / Jak3 protein, mouse; EC 2.7.10.2 / Janus Kinase 3; U86ZGC74V5 / Dimyristoylphosphatidylcholine

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Primary effusion lymphoma (PEL) is a rare non-Hodgkin's lymphoma (NHL) mostly occurring in HIV-positive patients.

We report two HIV-negative, HHV8-positive patients with PEL of the pleural cavity who achieved a durable remission after pleurodesis with bleomycin and no systemic therapy.

We also perform a review of the relevant literature regarding the clinical data, treatment, and survival of PEL in HIV-negative patients.

Genetic Alliance. consumer health - Primary effusion lymphoma.

Genetic Alliance. consumer health - HIV.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20150647.001).

[ISSN] 1791-7530

[Journal-full-title] Anticancer research

[ISO-abbreviation] Anticancer Res.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Greece

[Chemical-registry-number] 11056-06-7 / Bleomycin

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Primary effusion lymphoma (PEL) is a rare B-cell lymphoma caused by Kaposi's sarcoma-associated herpesvirus (KSHV).

PEL is poorly responsive to standard cytotoxic chemotherapy and portends a poor survival.

It is known that KSHV encodes two lytic genes, ORF36 (phosphotransferase) and KSHV ORF21 (thymidine kinase), which can phosphorylate ganciclovir and azidothymidine, respectively.

Here, we have explored whether these genes can be used as therapeutic targets for PEL.

PEL arises in pleural spaces and other effusions that provide a hypoxic environment.

Based on Northern blot analysis, exposure of PEL cells to hypoxia up-regulated the expression of both ORF36 and ORF21.

Using a newly developed nonradioactive reverse-phase high-performance liquid chromatography/mass spectrometry method to separate and quantify the phosphorylated forms of ganciclovir and azidothymidine, we found that PEL cells exposed to hypoxia produced increased amounts of the toxic triphosphates of these drugs.

Moreover, we found that hypoxia increased the cell toxicity of ganciclovir and azidothymidine in PEL cells but had no significant effect on the herpesvirus-negative cell line CA46.

These findings may have clinical applicability in the development of effective therapies for PEL or other KSHV-related malignancies.

MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. ZIDOVUDINE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17638913.001).

[ISSN] 0008-5472

[Journal-full-title] Cancer research

[ISO-abbreviation] Cancer Res.

[Language] eng

[Grant] United States / Intramural NIH HHS / /

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural

[Publication-country] United States

[Chemical-registry-number] 0 / Antiviral Agents; 4B9XT59T7S / Zidovudine; P9G3CKZ4P5 / Ganciclovir